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A combination of molecular modeling and structure–activity relationship studies has been used to 
fine-tune CB2 selectivity in the chromenopyrazole ring, a versatile CB1/CB2 cannabinoid scaffold. 
Thus, a series of 36 new derivatives covering a wide range of structural diversity has been 
synthesized, and docking studies have been performed for some of them. Biological evaluation of 
the new compounds includes, among others, cannabinoid binding assays, functional studies, and 
surface plasmon resonance measurements. The most promising compound [43 (PM226)], a 
selective and potent CB2 agonist isoxazole derivative, was tested in the acute phase of Theiler’s 
murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD), a well-established 
animal model of primary progressive multiple sclerosis. Compound 43 dampened 
neuroinflammation by reducing microglial activation in the TMEV.
Graphical abstract
INTRODUCTION
The endocannabinoid system (ECS) composed of at least two cannabinoid G-protein 
coupled receptors (CB1 and CB2 receptors),1,2 endogenous ligands such as anandamide and 
2-arachidonoylglycerol, and the enzymes for their biosynthesis and degradation, is involved 
in numerous physiological and pathological conditions.3–6 Therefore, for several years the 
ECS has been considered a potential therapeutic target for the clinical management of 
various disorders including inflammatory and neuropathic pain, neurological pathologies, 
and cancer among others.7 A few diseases can be treated nowadays with cannabinoid-based 
medicines, mainly, plant derived compounds. A mixture of synthetic tetrahydrocannabinol 
(Δ9-THC) [Figure 1] and nabilone, a Δ9-THC synthetic analogue, can be prescribed in 
several countries as antiemetic drugs for chemotherapy-induced nausea and vomiting8,9 and 
for anorexia10 treatment in patients with AIDS. A combination of Δ9-THC and cannabidiol 
is used for the symptomatic relief of spasticity in adults suffering multiple sclerosis and as 
an adjunctive analgesic treatment in adult patients with neuropathic pain or cancer.11 
Rimonabant, a CB1 receptor antagonist/inverse agonist, commercialized in 2006 for the 
management of obesity,12 was withdrawn a few years later because of the increase of 
depression, anxiety, headache, and suicidal thoughts. Even though the CB1/CB2 receptor 
agonists are currently in the forefront of clinical research for different applications, there is 
an increasing interest in exploiting novel pharmacological strategies.13 Whereas the CB1 
receptor is abundantly expressed in the central nervous system, the CB2 receptor is mainly 
associated with the peripheral immune system. The CB2 receptors are also expressed in the 
central nervous system in microglia and neuronal cells.14–18 Therefore, CB2 receptor 
selective agonists exhibit a promising therapeutic potential for treating various pathologies 
while avoiding the adverse psychotropic effects related to the modulation of the CB1 
receptors in the brain.19 Different therapeutic applications have been proposed for CB2 
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receptor agonists. Treatment of neuropathic20 and osteoarthritis pain,21 and diagnosis and 
treatment of osteoporosis22 are currently in advanced development.23 Activation of CB2 
receptors offers an attractive opportunity for treating neuroinflammatory events in 
neurological disorders, such as multiple sclerosis, cerebral ischemia, and Alzheimer’s and 
Parkinson’s diseases.13,24–31 Cannabinoid-based therapies are already approved for multiple 
sclerosis-associated symptoms such as pain and spasticity. The development of CB2 receptor 
ligands to regulate neural inflammation and neurogenesis in multiple sclerosis is much more 
recent.30,32
Different structures endowed with CB2 receptor affinity and partial or full selectivity were 
identified mainly by pharmaceutical companies through high throughput screening as 
reviewed recently by Han et al.33 In an attempt to target the CB2 type receptor, we decided 
to conduct structure–activity relationship studies around the chromenopyrazole scaffold. In 
previous studies, we had identified chromenopyrazoles as a novel cannabinoid scaffold 
which leads to nonpsychoactive and selective CB1 agonists with peripheral antinociceptive 
properties (Figure 1).34 On the basis of these previous findings, structural modifications 
around the chromenopyrazole have been explored to achieve CB2 receptor selectivity. From 
combined pharmacological and modeling studies, 36 new compounds covering structural 
diversity have been synthesized and evaluated. Among them, the most promising, 43, a fully 
selective CB2 agonist, has shown activity in the acute inflammatory phase of TMEV-IDD, a 
well-established animal model of primary progressive multiple sclerosis.35
Synthesis
Compounds 5–39 were synthesized as depicted in Scheme 1 from 7-(1,1-dimethylheptyl)-5-
hydroxy-3-(hydroxymethylen)-2,2-dimethylchroman-4-one (4). At the outset, chromanone 4 
was prepared by demethylation of the commercially available 5-(1,1-dimethylheptyl)-1,3-
dimethoxybenzene (1) followed by treatment with 3,3-dimethylacrylic acid and α-
formylation.34
Then, condensation of the β-ketoaldehyde 4 with the appropriate hydrazine gave the 
corresponding chromeno[4,3-c]pyrazol-9-oles 5–14 following a procedure previously 
published by us for 5–9.34 Two regioisomers, N1- and N2-substituted pyrazoles, can be 
formed and their structures could be observed thanks to the combined 1H, 13C, HSQC, and 
HMBC-NMR spectra. From alkylhydrazines, the regioisomers 7a/7b and 10a/10b were 
isolated with relative ratios varying from 1/5 to 2/1 (N1/N2). Condensation with 
hydroxymethylhydrazine only generated N2-pyrazole substitution (11) probably due to 
steric and electrostatic repulsions. In the case of arylhydrazines and cyclohexylhydrazine, 
the N1-regioisomers (8, 9, 12, and 13) were formed.
Preparation of compounds 15–39 was achieved by phenolic alkylation of the appropriate 
chromenopyrazoles (5–9) with the corresponding alkyl halide.
To explore the structure–activity relationships (SAR) on phenol substitution, 
conformationally restricted analogues (40 and 41) adopting a semiplanar geometry were 
synthesized as described in Scheme 2. Cyclodehydration of chromenopyrazoles 30 and 31 
with phosphorus pentoxide provided the desired condensed cyclic ethers 40 and 41.
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Further exploration of chromenopyrazoles as a scaffold led us to consider the bioisosteric 
replacement of the pyrazole into an isoxazole moiety. For that purpose, condensation of β-
diketone 4 with isoxazole 42 was efficiently achieved upon reaction with hydroxylamine 
hydrochloride as shown in Scheme 3. Phenolic alkylation of the chromenoisoxazole 42 




Chromenopyrazoles and chromenoisoxazoles 5–44 were evaluated for their ability to 
compete with the binding of the radiolabeled nonselective agonist [3H]-CP55,940 to human 
CB1 (hCB1) and CB2 (hCB2) cannabinoid receptors. As a source for these receptors, 
commercial membrane preparations of HEK293 cells stably expressing the respective 
receptor type were used. Tables 1–3 list the affinity constant values (Ki) for hCB1 and hCB2 
receptors obtained by fitting data from competition curves.
In prior studies, we have reported fully selective CB1 agonists 5–6 and 9.34 On the basis of 
these previous findings, we have explored the SAR around the chromenopyrazole scaffold in 
order to achieve affinity and selectivity for the other cannabinoid receptor type CB2. In the 
course of these studies, molecular modeling (discussed below) helped us to identify the 
structural features necessary to fine-tune CB2 affinity and selectivity. The best results in 
terms of CB2 affinity were obtained for the chromenopyrazole 34 and the 
chromenoisoxazole 42 with Ki < 6 nM. In what concerns CB2 receptor affinity and 
selectivity, the chromenoisoxazole 43 (PM226)36 showed CB2 selectivity with a Ki value of 
12.8 ± 2.4 nM.
In order to highlight SAR, the results may be discussed taking into account structural 
modifications on the pyrazole substituent (Table 1), on the phenol substituent (Table 2), and 
on the chromenopyrazole scaffold (Table 3).
The nature of the pyrazole substituent clearly influenced the affinity for cannabinoid 
receptors (Table 1). N-Methyl, N-ethyl, or unsubstituted chromenopyrazoles (5–7) bearing a 
free phenol group showed significant to high CB1 affinity and selectivity independently of 
the substitution position on the pyrazole ring (N1 or N2).34 N-Cyclohexyl substitution (14) 
drastically changed the selectivity profile exhibiting preference for the CB2 receptor. The 
role played by the cyclohexyl moiety for binding to the CB2 receptor is discussed later in the 
Molecular Modeling section. The presence of N-hydroxyalkyl groups (10a, 10b, and 11) 
resulted in moderate to high affinities for both receptors. Aromatic N-substituents (8, 9, 12, 
and 13) did not turn out to be beneficial for CB2 affinity.
Regarding the O-alkylated chromenopyrazoles (Table 2), in general, the loss of the free 
phenolic group led to compounds displaying high to moderate CB2 affinity and selectivity. 
Modeling studies on the hydroxychromenopyrazole 7b and methoxychromenopyrazole 18 
allowed us to determine critical interactions in the CB1 and CB2 receptor binding sites 
(discussed below).
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It is interesting to note that the condensation of a 2,4-dihydropyran to the 
chromenopyrazoles structure (40 and 41), which was performed for restricted 
conformational issues, elicited excellent CB2 selectivity even though they showed moderate 
affinity. In the O-alkylated series (Table 2), the pyrazole substitution contributes to 
determine affinity and selectivity issues. Unsubstituted pyrazoles 15, 22, 28, and 34 revealed 
high affinity toward both receptors regardless of the nature of the phenol substitution. N-
Aryl substitution (19, 20, 26, 27, 32, and 33) led to inactive derivatives, while N-methyl or 
ethyl substituents (16, 18, 23, 25, 28, 31, 35, and 39) resulted in high to moderate CB2 
affinity and selectivity independently of the nature of the phenol substituent. These results 
suggest that the CB2 receptor binding site does not tolerate bulky aromatic substituents on 
the pyrazole ring.
Bioisosteric replacement of the pyrazole by an isoxazole (Table 3) led to very potent 
cannabinoid ligands. Chromenoisoxazole 42 exhibited high affinity for both CB1 and CB2 
receptors with Ki values in the low nanomolar range (Ki CB1 = 15.4 nM; Ki CB2 = 5.3 nM). 
The fact that this isoxazole derivative (42) but not its pyrazole analogue (5) binds to the CB2 
receptor has been instrumental to propose a docking mode of these compounds to the active 
CB2 receptor model (CB2R*) as discussed in the Molecular Modeling section. Furthermore, 
these results and the data obtained for O-alkylated chromenopyrazoles prompted us to 
synthesize the methoxychromenoisoxazole 43, which resulted in the most potent and CB2 
selective ligand in this study, which was over 3000-fold selective for the CB2 receptor with 
an affinity constant of 12.8 nM. This CB2 affinity was similar to that of other selective 
synthetic CB2 receptor agonists, [(1R,2R,5R)-2-[2,6-dimethoxy-4-(2-methyloctan-2-
yl)phenyl]-7,7-dimethyl-4-bicyclo-[3.1.1]hept-3-enyl] methanol (HU-308)37 (Ki = 22.7 nM) 
or (6aR,10aR)-3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-
dibenzo[b,d]pyran (JWH-133)38 (Ki = 3.4 nM). Moreover, the selectivity of compound 43 
(CB1/CB2 > 3125) for CB2 receptor was higher than that of JWH-133 (CB1/CB2 = 200) or 
HU-308 (CB1/CB2 = 450).
Potency in Functional Assays
Compounds showing high affinity for the CB2 receptor (Ki values under 160 nM) (16–18, 
22, 28, 31, 34, 35, 37, 39, 41, 42, 43, and 44) were selected for functional evaluation in 
cAMP determination experiments. To further assess CB2 receptor activity through a different 
outcome, GTPγS binding assays of 34, 42–44 were performed.
Functional properties of CB2 ligands (16–18, 22, 28, 31, 34, 35, 37, 39, and 41–44) were 
appraised through cAMP assays using HEK293 cells stably expressing hCB2R and treated 
with forskolin to activate adenyl cyclase. Effects of tested compounds on forskolin-
stimulated cAMP levels were determined in a preliminary screening at two concentrations, 
at 200 nM and at 1 μM (Figure 2). The cannabinoid reference compound, 2-[(1R,2R,5R)-5-
hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol (CP55,940)39 was 
also tested in this assay as reference. Compounds 17, 18, 22, 28, 34, 37, 39, and 41–44 
displayed low to high inhibition of forskolin-stimulated cAMP accumulation at both 
concentrations. The tested compounds were also screened in normal HEK293 cells at the 
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same two concentrations to confirm that these effects were CB2 receptor-mediated 
(Supporting Information).
Full concentration–response curves were measured to determine IC50 and maximum 
inhibition values for the most potent compounds (34 and 41–44); the other compounds (17, 
18, 22, 28, 37, and, 39) behave as partial or weak agonists. As shown in Table 4, 34 and 41–
44 are potent CB2 agonists with IC50 values in the nanomolar range with chromenoisoxazole 
43 being the most potent and efficient (IC50 = 4.2 nM).
CB2 agonist properties of 34 and 42–44 were confirmed by [35S]-GTPγS binding assays 
performed in commercial CB2 receptor-containing membranes. The EC50 values obtained 
from the respective concentration–response curves are collected in Table 4. Agonist 
potencies of 34 and 42–44 vary from [35S]-GTPγS (EC50: 38.6–539.6 nM) to cAMP 
experiments (EC50: 4.2–134.0 nM) experiments. However, in both assay types, 
chromenoisoxazole 43 stood out to be the most potent selective CB2 receptor ligand of the 
series.
CB2 receptor ligands (16, 31, and 35) that in the preliminary screening exhibited no effect 
on forskolin-stimulated cAMP accumulation were tested for CB2R antagonism in cAMP 
assays. Compounds 16 and 35 were able to antagonize the effect of the cannabinoid agonist 
CP55,940 (100 nM and 1 μM) at a concentration of 200 nM, whereas 31 behaved as the 
CP55,940 antagonist only at the highest concentration (Figure 3).
In what concerns the CB1 receptor activity, only the effect of the new compounds showing 
the highest affinity for CB1 receptor (10b, 22, and 42) was determined. Potencies of 10b, 22, 
and 42 were evaluated through GTPγS binding assays performed in membranes extracted 
from HEK293 cells stably expressing the human CB1 receptor (Table 5). Tested compounds, 
10b, 22 and 42, produced an increase of basal [35S]-GTPγS binding, being 42 at least 10-
fold more potent than 10b and 22.
Molecular Modeling
During the course of our studies, cannabinoid selectivity and structural patterns led us to 
select molecules 5, 7b, 18, and 42 for docking studies. Given the high CB1 selectivity of the 
chromenopyrazole 5, it was surprising that the corresponding isoxazole derivative 42 showed 
high affinity for both cannabinoid receptors. Therefore, we report here docking studies of 
both compounds (5 and 42) in the refined CB1 and CB2 active state models. We also 
considered interesting that the replacement of the hydroxyphenyl by a methoxyphenyl led to 
full CB2 selectivity in the chromenopyrazole series. Varying degrees of CB2 selectivity and 
affinity were reported in the literature for some classical cannabinoids such as the HU-30837 
and methoxy-Δ8-THC derivatives.40 However, these 0-methylations have not been fully 
explored in terms of interactions with the binding site. Therefore, the CB1R selective 
chromenopyrazole 7b was studied in relation to its methoxy derivative 18 through docking 
studies.
First, conformational analysis of 5, 7b, 18, and 42 was performed to determine the global 
minimum energy conformers (Supporting Information). In what concerns the N-H-
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chromenopyrazole 5, this pyrazole can exist as a mixture of two tautomeric forms. However, 
we only considered the N2-H-tautomer based on our previous studies concerning annular 
tautomerism (OH···N and/or NH···O) of hydroxychromenopyrazoles, in which the tautomer 
OH···N was shown to be the predominant species in solution.41 We have then calculated the 
electrostatic potential maps of the minimum energy conformers of 5, 7b, 18, and 42 (Figure 
4). The phenolic hydroxyl group was revealed to be the most negative electrostatic potential 
region (in red) of 5 (CB1) and 7b (CB1). Chromenoisoxazole 42 (CB1/CB2) showed two 
electron rich hot spots (in red) originated by the phenolic hydroxyl group and by the 
isoxazole nitrogen, the latter being the most electronegative region of the molecule. As 
expected, the methoxychromenopyrazole 18 (CB2) displayed a weaker electronegative 
region due to the low exposure of the free lone pair of electrons of the methylated phenolic 
oxygen. A positive electrostatic potential at the corresponding region has also been detected 
for the highly CB2 selective ligand 43 (Supporting Information).
The global energy minima of 5, 7b, 18, and 42 were docked using a model of the CB1 and of 
the CB2 in their active state (CB1R*; CB2R*).42 These models include the extracellular and 
intracellular loops, the N-terminus (truncated in CB1R) and the C-terminus, including the 
intracellular helix portion of each receptor, termed Helix 8. Docking studies were performed 
in the same binding site described for HU21043 in the CB1R* model and for AM84144,45 in 
the CB2R* model.
Docking Studies of 5 and 42 in CB1R*—As illustrated in Figure 5, the energy-
minimized hydroxychromenopyrazole 5/CB1R* complex shows two main binding site 
anchoring interactions. The phenolic oxygen of 5 is engaged in a hydrogen bond with 
K3.28(192) [hydrogen bond (N–O) distance = 2.75 Å and (N–H–O) angle = 151°]. The N1-
pyrazole nitrogen establishes a hydrogen bond with serine S7.39(383) [hydrogen bond (N–
O) distance = 3.02 Å and (O–H–N) angle = 140°].
Docking 42 in CB1R* revealed a similar occupation of the binding site with hydrogen bonds 
involving K3.28(192) [hydrogen bond (N–O) distance = 2.82 Å and (N–H–O) angle = 153°] 
and S7.39(383) [ hydrogen bond (N–O) distance = 2.77 Å and (O–H–N) angle = 130°] as 
key residues (Figure 5, right). It is interesting to note that an additional hydrogen bond 
between the pyran oxygen and cysteine C7.42(386) was revealed in the 42/CB1R* complex 
[hydrogen bond (S–O) distance = 3.19 Å and (S–H–O) angle = 167°].
Docking Studies of 5 and 42 in CB2R*—The CB2R* model contains a salt bridge 
between the aspartic acid D275 in the EC-3 loop and lysine K3.28(109). Docking studies of 
5 revealed a steric clash between the pyrazole moiety of the structure and the lysine involved 
in the ionic lock (Figure 6, left) and in agreement with the experimental pharmacological 
data (Ki (CB2R) > 40 μM), whereas the energy minimized 42/CB2R* complex presents two 
main interactions (Figure 6, right), a hydrogen bond between the isoxazole nitrogen and 
K3.28(109) [hydrogen bond (N–O) distance =2.86 Å and (N–H–O) angle = 157°] and a 
hydrogen bond involving the phenolic oxygen of 42 and S6.58(268) [hydrogen bond (O–O) 
distance = 2.63 Å and (O–H–O) angle = 170°].
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Docking Studies of 7b and 18 in CB1R*—The hydroxychromenopyrazole 7b and the 
methoxychromenopyrazole 18 were compared at the CB1R* binding site (Supporting 
Information). The 7b/CB1R* complex presents two hydrogen bonds with K3.28(192) that 
involve the phenolic oxygen and the pyrazole N1 nitrogen which also forms a hydrogen 
bond with S7.39(383). Consistent with its poor CB1 affinity, 18 was unable to form any 
hydrogen bond with any residue of the receptor. Indeed, the methoxy group of 18 shows 
steric overlap with the phenylalanine F2.57(170) and the leucine L7.43(387) inducing low 
accessibility of the lone pairs of electrons of the phenolic oxygen to K3.28(192) (shown in 
the Supporting Information).
Docking Studies of 7b and 18 in CB2R*—Figure 7 illustrates the CB2R* docking 
studies of 7b and 18. As previously shown for the 5/CB2R* complex, the 
hydroxychromenopyrazole 7b exhibits a steric clash between the pyrazole moiety and the 
ionic lock formed by D275 and K3.28(109) with an additional major steric overlap with 
F7.35(281). These findings likely explain the lack of affinity of chromenopyrazole 7b for the 
CB2 receptor. The methoxy derivative 18 displays similar occupation of the binding site; 
however, 18 adopts a different orientation than the free phenolic hydroxyl ligands 5, 42, and 
7b. This orientation enables S6.58(268) to form a hydrogen bond with the pyran oxygen 
[hydrogen bond (O–O) distance = 3.21 Å and (O–H–O) angle = 110°].
The results obtained with our docking studies in the CB2R* model reveal the importance of 
two residues, S6.58(268) and K3.28(109). The serine S6.58 had been previously mentioned 
in the interactions of the classical cannabinoid AM84148 with CB2R*.45 However, the 
phenolic hydroxyl of AM841 participated in this interaction. In what concerns the lysine 
K3.28, its importance to classical cannabinoid binding to CB1R* is well documented,49 
whereas K3.28 was considered not essential to bind to CB2R*.45 As shown in our docking 
studies, K3.28 establishes a hydrogen bond with the isoxazole nitrogen in the 42/CB2R* 
complex.
Furthermore, the docking studies suggested that substitution of the hydroxyl phenol of the 
potent CB1/CB2 compound 42 would lead to a selective CB2 ligand, as was confirmed by 
the synthesis of 43 which turned out to be the most interesting of the series.
Drug-Like Properties in Silico
Multivariate statistical analysis of a relative large set of 34 physicochemical descriptors 
calculated on the global minimum energy conformer of the chromenopyrazoles and 
chromenoisoxazoles 5–44, cannabinol (CBN), CP55,940, and Δ9-THC has been realized 
which data were compared to a range of 95% of drugs. The predicted data (Supporting 
Information) for the chromenoheterocycle derivatives indicated that Lipinski’s and 
Jorgensen’s pharmacokinetics rules are followed. One of the physicochemical properties that 
need to be optimized for cannabinoids is the lipophilicity, as it is an important factor 
affecting its bioavailability. Therefore, it is predicted that the chromenoisoxazoles 42–44 
have a better bioavailability profile compared to that of classical cannabinoids such as 9Δ-
THC or CBN calculated in the same predictive model. In what concerns the blood–brain 
barrier, predictive data of the compounds suggest that they can cross this barrier.
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Assessment of the Binding of Compounds to Plasma Proteins
Surface plasmon resonance (SPR) experiments were performed with a Biacore X–100 
apparatus to study the different binding levels of selected compounds (14, 16–18, 28, 31, 
35–37, 39, and 41–43) to two plasma proteins, human serum albumin (HSA) and α1-acid 
glycoprotein (AGP). As this experiment had not been previously reported in the literature for 
cannabinoids, different reference cannabinoid ligands (rimonabant, SR144528,50 
WIN55,212–2,51 HU308, CBD, 2-AG, AEA, and CP55,940) were also assessed for 
comparison. The results (Supporting Information) indicated that 14–16, 39, 40, and 43 could 
exhibit medium HSA and AGP binding levels suggesting appropriate free drug 
concentrations in plasma, whereas 18, 28, 36, 37, and 42 showed very high plasma protein 
binding that, if any, could be of interest for in vivo retarding effects. The tested reference 
cannabinoid ligands CBD, 2AG, and AEA showed very high levels of binding to AGP, 
whereas CBD, 2-AG, and CP55,940 showed high levels of binding to HSA. It has to be kept 
in mind that cannabinoids are, in general, very lipophilic compounds.
In Vivo Efficacy of 43 in the Acute Inflammatory Phase of a Multiple Sclerosis Animal 
Model
One of the most promising therapeutic applications of cannabinoids selectively activating 
the CB2 receptor is the reduction of neuroinflammatory events.52 Thus, we wanted to 
investigate the potential in vivo of 43 in experimental models reproducing 
neuroinflammatory conditions. Multiple sclerosis is a complex inflammatory disease that 
affects the CNS white matter. The Theiler’s murine encephalomyelitis virus (TMEV) model 
is one of the best viral-based models of multiple sclerosis. Intracerebral infection of 
susceptible inbred mouse strains with TMEV leads to the induction of a late-onset 
demyelinating disease, termed TMEV-induced demyelinating disease (TMEV-IDD) which is 
pathologically similar to human multiple sclerosis. The acute inflammatory phase of TMEV-
IDD (day 7 post infection) has a strong neuroinflammatory response with the participation 
of microglial cells as antigen presenting cells of viral antigens. To assess the efficacy of 43, 
mice infected with TMEV for 7 consecutive days were injected intraperitoneally with 
vehicle (10% DMSO in phosphate-buffered saline, PBS) or 43 at a dose of 5 mg/kg. Brain 
sections of each animal (described in Experimental Section) were analyzed by 
immunofluorescence staining. Because microglial cell activation plays a pivotal role in 
TMEV-IDD,35 we analyzed the effect of 43 on the expression of Iba-1, a marker of 
microglia, in the brain of TMEV-infected mice. As illustrated in Figure 8, fluorescent 
staining revealed that TMEV-infection increased the intensity of fluorescence of Iba-1+ cells 
in the brain. Microglia activation was greatly prevented by administration of 43 leading to a 
significant reduction of the intensity of microglia activation to levels close to those 
quantified in the control group (Sham, Figure 8). Therefore, we can conclude that 
administration of 43 significantly reduced microglial activation in TMEV-infected mice that 
based on previous studies35 should necessarily reduce inflammatory events and improve the 
neurological status of treated animals.
Compound 43 has been also recently evaluated with positive results in inflammatory models 
of Huntington’s disease that will be published in due time.
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The pharmacological and docking studies carried out with the newly synthesized 
chromenopyrazoles and -isoxazoles along with our earlier findings allowed us to determine 
key structural features for CB2 receptor binding. O-Alkylated chromenopyrazoles led to 
compounds displaying high to moderate CB2 affinity and selectivity vs CB1, whereas 
replacement of the pyrazole core by an isoxazole led to very potent cannabinoid ligands. 
Even though different degrees of CB2 selectivity and affinity were reported in the literature 
for classical cannabinoids, their binding site interactions have not been fully explored.45 The 
results obtained with our docking studies in the CB2R* model reveal the importance of two 
residues, S6.58(268) and K3.28(109). The serine S6.58 that had been previously described 
as interacting with the phenolic hydroxyl of classical cannabinoid,45 established a hydrogen 
bond with the pyran oxygen and our compounds. The residue K3.28 that was considered not 
essential for classical cannabinoids to bind to CB2R*45 formed a hydrogen bond with the 
isoxazole nitrogen that conferred CB2 affinity to the chromenoisoxazole compared to the 
corresponding chromenopyrazole. Finally, these studies led to the synthesis of the 
chromenoisoxazole 43 that was shown to be fully CB2 selective with a high affinity constant.
Multiple sclerosis is the major immune-mediated, demyelinating and neurodegenerative 
disease of the central nervous system (CNS). A mixture of Δ9-THC and a cannabidiol 
oromucosal spray has shown clinical benefit in reducing spasticity symptoms in multiple 
sclerosis, and it is now licensed for the treatment of multiple sclerosis symptoms. However, 
there is now abundant experimental evidence that cannabinoids can act as 
inmunomodulators and neuroprotective agents in both in vitro and in vivo models of 
neurodegeneration.30 In particular, the CB2 receptor has been associated with the anti-
inflammatory and immunomodulatory actions exerted by cannabinoids53 and has been 
suggested to play a role in multiple sclerosis models.54,55 The modulation of the innate 
immunity including microglia responses to TMEV infection by cannabinoid treatment 
affected the development and progression of disabilities in the TMEV-IDD model.35,56 In 
this context, compound 43 has been tested in the acute inflammatory phase of the TMEV 
model. Administration of 43 significantly reduced microglial activation.
EXPERIMENTAL SECTION
Chemistry. General Methods and Materials
Reagents and solvents were purchased from Sigma-Aldrich Co., Fluorochem, Acros 
Organics, Manchester Organics, or Lab-Scan and were used without further purification or 
drying. Silica gel 60 F254 (0.2 mm) thin layer plates were purchased from Merck GmbH. 
Microwave assisted organic synthesis was performed using the microwave reactor Biotage 
Initiator. Products were purified using flash column chromatography (Merck Silica gel 60, 
230–400 mesh) or medium pressure chromatography using Biotage Isolera One with 
prepacked silica gel columns (Biotage SNAP cartridges). The compounds were 
characterized by a combination of NMR experiments, HPLC-MS, high-resolution mass 
spectrometry (HRMS), and elemental analysis. HPLC-MS analysis was performed on a 
Waters 2695 HPLC system equipped with a photodiode array 2996 coupled to Micromass 
ZQ 2000 mass spectrometer (ESI-MS), using a reverse-phase column SunFireTM (C-18, 4.6 
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× 50 mm, 3.5 μm) in a 10 min gradient A, CH3CN/0.1% formic acid, and B, H2O/0.1% 
formic acid visualizing at λ = 254 nm. The flow rate was 1 mL/min. Elemental analyses of 
the compounds were performed using a LECO CHNS-932 apparatus. Deviations of the 
elemental analysis results from the calculated one are within ±0.4%. 1H, 13C, HSQC, and 
HMBC-NMR spectra were recorded on a Bruker 300 (300 and 75 MHz) or a Varian 500 
(500 and 126 MHz) at 25 °C. Samples were prepared as solutions in deuterated solvent and 
referenced to internal nondeuterated solvent peaks. Chemical shifts were expressed in ppm 
(δ) downfield of tetramethylsilane. Coupling constants are given in hertz (Hz). Melting 
points were measured on a MP 70 Mettler Toledo apparatus. The synthesis of compounds 2–
9 have been previously described by us.34
General Procedure for the Preparation of 10, 12–14—A solution of 434 (1 mmol) 
and the corresponding hydrazine (2.5 mmol) in EtOH was stirred during 4 h at 40 °C. The 
solvent was evaporated under reduced pressure, and the crude was purified by column 
chromatography on silica gel.
7-(1,1-Dimethylheptyl)-1,4-dihydro-1-(2-hydroxyethyl)-4,4-dimethylchromeno[4,3-
c]pyrazol-9-ol (10a) and 7-(1,1-Dimethyl-heptyl)-2,4-dihydro-2-(2-hydroxyethyl)-4,4-
dimethylchrome-no[4,3-c]pyrazol-9-ol (10b): The title compounds were prepared from 2-
hydroxyethylhydrazine with column chromatography on silica gel (hexane/EtOAc, 2:3). 
Compound 1.9a was obtained as a white oil (10 mg, 23%). 1H NMR (300 MHz, CDCl3) δ: 
8.15 (s, 1H, 9-OH), 7.30 (s, 1H, 3-H), 6.62 (d, J = 1.6 Hz, 1H, 8-H), 6.53 (d, J = 1.6 Hz, 1H, 
6-H), 4.29 (t, J = 5.7 Hz, 2H, NCH2CH2OH), 4.10–4.03 (m, 2H, NCH2CH2OH), 1.65 (s, 
6H, OC(CH3)2), 1.62–1.52 (m, 2H, 2′-H), 1.28 (s, 6H, C(CH3)2), 1.25–1.17 (m, 6H, 3′-H, 
4′-H, 5′-H), 1.16–1.00 (m, 2H, 6′-H), 0.87 ppm (t, J = 6.6 Hz, 3H, 7′-H). 13C NMR (75 
MHz, CDCl3) δ: 152.9 (9-C), 152.6 (7-C), 152.4 (5a-C), 143.0 (9b-C), 124.2 (3-C), 120.0 
(3a-C), 106.4 (8-C), 106.1 (6-C), 100.8 (9a-C), 76.1 (OC(CH3)2), 61.4 (NCH2CH2OH), 54.0 
(NCH2CH2OH), 44.2 (2′-C), 37.8 (C(CH3)2), 31.5, 29.7, 24.4 (3′-C, 4′-C, 5′-H), 29.3 
(C(CH3)2), 28.6 (OC(CH3)2), 22.4 (6′-C), 13.8 ppm (7′-C). HPLC-MS: [A, 70 → 95%]. 
tR: 5.11 min, (95%); MS (ES+, m/z) 387 [M + H]+. Anal. Calcd for C23H34N2O3: C 71.47, 
H 8.87; found, C 71.19, H 9.04. Compound 10b was obtained as a yellow solid (22 mg, 
50%). mp: 93–95 °C. 1H NMR (300 MHz, CDCl3) δ: 7.38 (s, 1H, 3-H), 6.63 (d, J = 1.8 Hz, 
1H, 8-H), 6.50 (d, J = 1.9 Hz, 1H, 6-H), 4.63 (t, J = 5.0 Hz, 2H, NCH2CH2OH), 4.12 (t, J = 
5.0 Hz, 2H, NCH2CH2OH), 1.57 (s, 6H, OC(CH3)2), 1.25 (s, 6H, C(CH3)2), 1.21–1.16 (m, 
8H, 2′-H, 3′-H, 4′-H, 5′-H), 1.13–1.00 (m, 2H, 6′-H), 0.83 ppm (t, J = 6.5 Hz, 3H, 7′-
H). 13C NMR (75 MHz, CDCl3) δ: 154.4 (9-C), 153.4 (7-C), 150.4 (5a-C), 149.9 (9b-C), 
133.7 (3-C), 123.3 (3a-C), 109.3 (6-C), 108.8 (8-C), 102.9 (9a-C), 76.8 (OC(CH3)2), 62.1 
(NCH2CH2OH), 53.5 (NCH2CH2OH), 44.6 (2′-C), 38.0 (C(CH3)2), 32.0, 30.2, 25.9 (3′-C, 
4′-C, 5′-H), 28.9 (OC(CH3)2), 27.5 (C(CH3)2), 22.9 (6′-C), 14.3 ppm (7′-C); HPLC-MS: 
[A, 70 → 95%]. tR: 3.93 min, (99%); MS (ES+, m/z) 387 [M + H]+. Anal. Calcd for 
C23H34N2O3: C 71.47, H 8.87; found, C 71.62, H 8.96.
7-(1,1-Dimethylheptyl)-2,4-dihydro-2-hydroxymethyl-4,4-dimethylchromeno[4,3-
c]pyrazol-9-ol (11): Formaldehyde (37% in water, 13 μL, 0.17 mmol) was added to 
chromenopyrazole 5 (20 mg, 0.05 mmol) dissolved in ethanol (2 mL). The mixture was 
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heated under reflux for 5 h and then cooled down to room temperature. After evaporation of 
the solvent under reduced pressure, the crude was purified by chromatography on silica gel 
(hexane/EtOAc, 1:1). Compound 11 was obtained as a white solid (14 mg, 69%). mp: 90–
92 °C. 1H NMR (300 MHz, CDCl3) δ: 7.35 (s, 1H, 3-H), 6.59 (d, J = 1.6 Hz, 1H, 8-H), 6.51 
(d, J = 1.6 Hz, 1H, 6-H), 5.30 (s, 2H, NCH2OH), 1.64 (s, 6H, OC(CH3)2), 1.61–1.49 (m, 2H, 
2′-H), 1.25 (s, 6H, C(CH3)2), 1.23–0.94 (m, 6H, 3′-H, 4′-H, 5′-H), 0.81 ppm (t, J = 4.8 Hz, 
3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 151.7 (9-C), 150.6 (7-C), 149.1 (5a-C), 148.2 
(9b-C), 127.0 (3-C), 124.7 (3a-C), 110.1 (6-C), 109.3 (8-C), 104.9 (9a-C), 75.4 (OC(CH3)2), 
65.8 (NCH2OH), 43.2 (2′-C), 39.5 (C(CH3)2), 32.5, 31.6, 25.5 (3′-C, 4′-C, 5′-C), 28.9 
(OC(CH3)2), 27.4 (C(CH3)2), 23.7 (6′-C), 14.7 ppm (7′-C). HPLC-MS: [A, 80 → 95%]. 
tR: 3.42 min (96%); MS (ES+, m/z) 373 [M + H]+. Anal. Calcd for C22H32N2O3: C 70.94, H 
8.66; found, C 71.12, H 8.93.
1-(3,5-Difluorophenyl)-7-(1,1-dimethylheptyl)-1,4-dihydro-4,4-dimethylchromeno[4,3-
c]pyrazol-9-ol (12): The title compound was prepared from 3,5-difluorophenylhydrazine 
hydrochloride. Column chromatography on silica gel (hexane/EtOAc, 3:1) afforded 12 as a 
yellow oil (32 mg, 82%). 1H NMR (300 MHz, CDCl3) δ: 7.55 (s, 1H, 3-H), 7.10–6.98 (m, 
3H, 2-HPh, 4-HPh, 6-HPh), 6.65 (d, J = 1.9 Hz, 1H, 6-H), 6.70 (d, J = 1.9 Hz, 1H, 8-H), 1.62 
(s, 6H, OC(CH3)2), 1.49–1.43 (m, 2H, 2′-H), 1.26 (s, 6H, C(CH3)2), 1.19–1.08 (s, 8H, 3′-H, 
4′-H, 5′-H, 6′-H), 0.93–0.85 ppm (m, 3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 155.2 (9-
C), 154.0 (5a-C), 152.6 (7-C), 141.7 (1-CPh), 136.3 (3-C), 135.7 (3-CPh), 135.4 (3-CPh), 
134.2 (9b-C), 130.1, 128.7, 126.0 (2-CPh, 4-CPh, 6-CPh), 122.9 (3a-C), 109.3 (6-C), 108.1 
(8-C), 103.9 (9a-C), 75.6 (OC(CH3)2), 44.0 (2′-C), 38.8 (C(CH3)2), 32.6, 31.0, 25.7, 23.2 
(3′-C, 4′-C, 5′-C, 6′-C), 28.7 (C(CH3)2), 27.4 (OC(CH3)2), 15.1 ppm (7′-C). HPLC-MS: 
[A, 80% → 95%]. tR: 4.22 min (99%). MS (ES+, m/z) 455 [M + H]+. Anal. Calcd for 
C27H32F2N2O2: C 71.34, H 7.10; found, C 71.02, H 6.95.
7-(1,1-Dimethylheptyl)-1,4-dihydro-1-(3-methoxyphenyl)-4,4-dimethylchromeno[4,3-
c]pyra-zol-9-ol (13): The title compound was prepared from 3-methoxyphenylhydrazine 
hydrochloride. Column chromatography on silica gel (hexane/EtOAc, 3:1) afforded 13 as a 
yellow oil (48 mg, 47%). 1H NMR (300 MHz, CDCl3) δ: 7.47 (s, 1H, 3-H), 7.32 (t, J = 7.5 
Hz, 1H, 5-HPh), 7.27 (t, J = 1.7 Hz, 1H, 2-HPh), 7.18–7.13 (m, 1H, 6-HPh), 7.01–6.96 (m, 
1H, 4-HPh), 6.60 (d, J = 1.8 Hz, 1H, 6-H), 6.53 (d, J = 1.8 Hz, 1H, 8-H), 3.75 (s, 3H, OCH3), 
1.63 (s, 6H, OC(CH3)2), 1.60–1.52 (m, 2H, 2′-H), 1.31–1.20 (m, 12H, 3′-H, 4′-H, 5′-H, 
C(CH3)2), 1.16–1.09 (m, 2H, 6′-H), 0.89–0.79 ppm (m, 3H, 7′-H). 13C NMR (75 MHz, 
CDCl3) δ: 156.1 (9-C), 154.1 (3-CPh), 150.9 (5a-C), 141.2 (7-C), 138.2 (1-CPh), 136.2 (3-
C), 133.4 (9b-C), 130.2 (5-CPh), 123.4 (6-CPh), 122.3 (4-CPh), 120.3 (3a-C), 109.0 (2-CPh), 
108.6 (6-C), 105.0 (8-C), 103.4 (9a-C), 75.0 (OC(CH3)2), 56.3 (OCH3), 44.8 (2′-C), 38.7 
(C(CH3)2), 31.7, 30.2, 26.1 (3′-C, 4′-C, 5′-C), 28.9 (C(CH3)2), 27.6 (OC(CH3)2), 23.0 (6′-
C), 14.3 ppm (7′-C). HPLC-MS: [A, 80 → 95%]. tR: 3.81 min (94%). MS (ES+, m/z) 449 
[M + H]+. Anal. Calcd for C28H36N2O3: C 74.97, H 8.09; found, C 75.06, H 7.78.
1-Cyclohexyl-7-(1,1-dimet h ylhepty l)-1,4-dihy dro-4,4-dimethylchromeno[4,3-
c]pyrazol-9-ol (14): Prepared from cyclohexylhydrazine hydrochloride (0.12 g, 0.80 mmol). 
Column chromatography on silica gel (hexane/EtOAc, 2:1) afforded compound 14 as a pale-
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yellow solid (39 mg, 35%). mp: 98–100 °C. 1H NMR (300 MHz, CDCl3) δ: 7.38 (s, 1H, 3-
H), 6.62 (d, J = 1.7 Hz, 1H, 6-H), 6.57 (d, J = 1.7 Hz, 1H, 8-H), 4.61–4.52 (m, 1H, Ha), 
1.86–1.80 (m, 4H, Hb and Hf), 1.76–1.69 (m, 6H, Hc, Hd, He), 1.64 (s, 6H, OC(CH3)2), 
1.49–1.44 (m, 2H, 2′-H), 1.24 (s, 6H, C(CH3)2), 1.19–1.08 (m, 8H, 3′-H, 4′-H, 5′-H, 6′-
H), 0.92–0.86 ppm (m, 3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 152.8 (9-C), 151.6 (7-C), 
149.9 (5a-C), 134.8 (9b-C), 130.6 (3-C), 125.3 (3a-C), 109.3 (8-C), 106.1 (6-C), 103.2 (9a-
C), 75.7 (OC(CH ) ), 50.3 (C ), 43.1 (2′-C), 38.2 (C(CH3)2), 32.6 (Cb, Cf), 31.6, 31.0, 24.0, 
22.8 (3′-C, 4′-C, 5′-C, 6′-C), 28.9 (C(CH3)2), 27.7 (OC(CH3)2), 26.9, 26.3 (Cc, Cd,Ce), 
14.7 ppm (7′-C). HPLC-MS: [A, 80 → 95%]. tR: 5.02 min, (97%). MS (ES+, m/z) 426 [M 
+ H]+. Anal. Calcd for C27H40N2O2: C 76.37, H 9.50; found, C 76.11, H 9.74.
General Procedure for the Preparation of 15–39—A solution of the selected 
hydroxychromenopyrazole from 5–9 (1 equiv) in anhydrous THF was added dropwise to a 
precooled suspension of sodium hydride (1.6 equiv) in anhydrous THF under nitrogen 
atmosphere. The resulting yellow solution was stirred for 10 min at rt. Then, the 
corresponding alkylating agent (3–5 equiv) was rapidly added. The reaction mixture was 
refluxed for 1–12 h. The crude was diluted with diethyl ether or EtOAc, filtered, 
concentrated under vacuum, and purified on column chromatography on silica gel.
7-(1,1-Dimethylheptyl)-2,4-dihydro -9-methoxy-4 ,4-dimethylchromeno[4,3-c]pyrazole 
(15): The title compound was prepared from 5 and iodomethane. Column chromatography 
on silica gel (hexane/EtOAc, 3:1) afforded 15 as a yellow oil (21 mg, 40%). 1H NMR (300 
MHz, CDCl3) δ: 8.13–8.09 (br s, 1H, NH), 7.31 (d, J = 1.5 Hz, 1H, 6-H), 7.19 (d, J = 1.5 
Hz, 8-H), 6.74 (s, 1H, 3-H), 3.95 (s, 3H, OCH3), 1.69–1.60 (br s, 6H, OC(CH3)2), 1.60–1.56 
(m, 2H, 2′-H), 1.39 (s, 6H, C(CH3)2), 1.25–1.22 (m, 6H, 3′-H, 4′-H, 5′-H), 1.17–1.08 (m, 
2H, 6′-H), 0.81 ppm (t, J = 6.7 Hz, 3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 157.0 (9-C), 
155.4 (5a-C), 154.1 (7-C), 143.2 (9b-C), 125.6 (3-C), 120.1 (3a-C), 108.0 (8-C), 107.5 (6-
C), 102.3 (9a-C), 76.8 (OC(CH3)2), 49.6 (OCH3), 43.7 (2′-C), 40.2 (C(CH3)2), 37.2, 34.7, 
24.6 (3′-C, 4′-C, 5′-C), 29.1 (C(CH3)2), 28.3 (OC(CH3)2), 22.7 (6′-C), 15.1 ppm (7′-C). 
HPLC-MS: [A, 80% → 95%]. tR: 5.41 min, (97%); MS (ES+, m/z) 357 [M + H]+. Anal. 
Calcd for C22H32N2O2: C 74.12, H 9.05; found, C 74.35, H, 8.87.
7-(1,1-Dimethylheptyl)-2,4-dihydro-9-methox y-2,4,4-trimethylchromeno[4,3-
c]pyrazole (16): The title compound was prepared from 6b and iodomethane. Column 
chromatography on silica gel (hexane/EtOAc, 2:1) afforded 16 as a white solid (17 mg, 
68%). mp: 85–87 °C. 1H NMR (300 MHz, CDCl3) δ: 7.63 (s, 1H, 3-H), 6.91 (d, J = 1.8 Hz, 
1H, 6-H), 6.76 (d, J = 1.8 Hz, 1H, 8-H), 4.02 (s, 3H, NCH3), 3.90 (s, 3H, OCH3), 1.59 (s, 
6H, OC(CH3)2), 1.45–1.36 (m, 2H, 2′-H), 1.30 (s, 6H, C(CH3)2), 1.2–1.13 (m, 6H, 3′-H, 
4′-H, 5′-H), 1.10–1.03 (m, 2H, 6′-H), 0.87 ppm (t, J = 7.0 Hz, 3H, 7′-H). 13C NMR (75 
MHz, CDCl3) δ: 153.2 (9-C), 152.6 (5a-C), 151.8 (7-C), 142.1 (9b-C), 124.3 (3-C), 122.0 
(3a-C), 109.5 (6-C), 105.7 (8-C), 103.1 (9a-C), 76.2 (OC(CH3)2), 57.0 (OCH3), 45.3 
(NCH3), 39.2 (2′-C), 37.8 (C(CH3)2), 32.0, 31.3, 25.3 (3′-C, 4′-C, 5′-C), 29.5 (C(CH3)2), 
27.8 (OC(CH3)2), 23.5 (6′-C), 13.8 ppm (7′-C). HPLC-MS: [A, 80% → 95%]. tR: 3.58 min 
(99%). MS (ES+, m/z) 371 [M + H]+. Anal. Calcd for C23H34N2O2: C 74.55, H 9.25; found, 
C 74.89, H, 8.96.
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c]pyrazole (17): The title compound was prepared from 6b and iodomethane. Column 
chromatography on silica gel (hexane/EtOAc, 3:1) afforded 17 as a white solid (13 mg, 
52%). mp: 90–91 °C. 1H NMR (300 MHz, CDCl3) δ: 7.34 (s, 1H, 3-H), 6.70 (d, J = 1.5 Hz, 
2H, 6-H), 6.52 (d, J = 1.5 Hz, 1H, 8-H), 4.42 (q, J = 7.9 Hz, 2H, NCH2CH3), 3.81 (s, 3H, 
OCH3), 1.60 (s, 6H, OC(CH3)2), 1.54–1.50 (m, 2H, 2′-H), 1.45 (t, J = 7.9 Hz, 3H, 
NCH2CH3), 1.31 (s, 6H, C(CH3)2), 1.24–1.19 (br s, 8H, 3′-H, 4′-H, 5′-H, 6′-H), 0.86 ppm 
(t, J = 8.0 Hz, 3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 153.0 (9-C), 152.6 (5a-C), 150.4 
(7-C), 132.3 (3-C), 131.7 (9b-C), 121.9 (3a-C), 109.0 (8-C), 105.3 (6-C), 101.1 (9a-C), 76.8 
(OC(CH3)2), 54.5 (OCH3), 49.6 (NCH2CH3), 43.9 (2′-C), 38.4 (C(CH3)2), 31.8, 30.5, 26.0 
(3′-C, 4′-C, 5′-C), 28.7 (C(CH3)2), 26.9 (OC(CH3)2), 22.9 (6′-C), 15.8 (NCH2CH3), 14.6 
ppm (7′-C). HPLC-MS: [A, 15% - 95%]. tR: 5.81 min (98%). MS (ES+, m/z) 385 [M + H]+. 
Anal. Calcd for C24H36N2O2: C 74.96, H 9.44; found, C 74.57, H 9.25.
7-(1,1-Dimethylheptyl)-2-ethyl-2,4-dihydro-9-methoxy-4,4-dimethylchromeno[4,3-
c]pyrazole (18): The title compound was prepared from 7b and iodomethane. Column 
chromatography on silica gel (hexane/EtOAc, 1:1) afforded 18 as a white solid (20 mg, 
77%). mp: 87–88 °C. 1H NMR (300 MHz, CDCl3) δ: 7.09 (s, 1H, 3-H), 6.50 (d, J = 1.3 Hz, 
8-H), 6.37 (s, 1H, J = 1.3 Hz, 6-H), 4.19 (q, 2H, J = 7.2 Hz, NCH2CH3), 3.90 (s, 3H, OCH3), 
1.64 (s, 6H, OC(CH3)2), 1.57–1.54 (br s, 2H, 2′-H), 1.53 (t, 3H, J = 7.6 Hz, NCH2CH3), 
1.27 (s, 6H, C(CH3)2), 1.20–1.11 (m, 6H, 3′-H, 4′-H, 5′-H), 1.09–1.04 (br s, 2H, 6′-H), 
0.83 ppm (t, J = 7.8 Hz, 3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 155.3 (9-C), 154.0 (5a-
C), 153.8 (7-C), 143.7 (9b-C), 128.2 (3-C), 126.1 (3a-C), 107.4 (6-C), 106.8 (8-C), 103.7 
(9a-C), 78.0 (OC(CH3)2), 56.8 (OCH3), 47.3 (NCH2CH3), 45.7 (2′-C), 39.0 (C(CH3)2), 
32.3, 31.1, 25.7 (3′-C, 4′-C, 5′-C), 29.1 (C(CH3)2), 27.4 (OC(CH3)2), 23.3 (6′-C), 16.2 
(NCH2CH3), 14.0 ppm (7′-C). HPLC-MS: [A, 80%–95%]. tR: 3.95 min (99%). MS (ES+, 
m/z) 385 [M + H]+. Anal. Calcd for C24H36N2O2: C 74.96, H 9.44; found, C 75.02, H 9.18.
1-(3,4-Dichlorophenyl)-7-(1,1-dimethylheptyl)-1,4-dihydro-9-methoxy-4,4-
dimethylchrome-no[4,3-c]pyrazole (19): The title compound was prepared from 8 and 
iodomethane. Column chromatography on silica gel (hexane/EtOAc, 1:1) afforded 19 as a 
yellow oil (11 mg, 47%). 1H NMR (300 MHz, CDCl3) δ: 7.81 (d, J = 1.9 Hz, 1H, 2-HPh), 
7.72 (s, 1H, 3-H), 7.49 (d, J = 7.8 Hz, 1H, 5-HPh), 7.37 (dd, J = 7.8 Hz, J = 1.9 Hz, 1H, 6-
HPh), 6.74 (d, J = 1.4 Hz, 1H, 6-H), 6.30 (d, J = 1.4 Hz, 1H, 8-H), 3.28 (s, 3H, OCH3), 1.72 
(s, 6H, OC(CH3)2), 1.68–1.60 (m, 2H, 2′-H), 1.39 (s, 6H, C(CH3)2), 1.27–1.18 (m, 6H, 3′-
H, 4′-H, 5′-H), 1.12–1.08 (br s, 2H, 6′-H), 0.91 ppm (t, J = 7.1 Hz, 3H, 7′-H). 13C NMR 
(75 MHz, CDCl3) δ: 154.2 (9-C), 153.8 (5a-C), 152.1 (7-C), 143.1 (1-CPh), 135.7 (3-C), 
134.2 (3-CPh), 132.6 (9b-C), 130.8 (4-CPh), 126.3 (5-CPh), 125.9 (2-CPh), 124.0 (6-CPh), 
120.1 (3a-C), 109.3 (6-C), 108.4 (8-C), 103.5 (9a-C), 76.1 (OC(CH3)2), 54.9 (OCH3), 43.5 
(2′-C), 39.0 (C(CH3)2), 33.9, 32.3, 26.8 (3′-C, 4′-C, 5′-C), 28.3 (C(CH3)2), 27.1 
(OC(CH3)2, 22.7 (6′-C), 14.0 ppm (7′-C). HPLC-MS: [A, 80% → 95%]. tR: 11.13 min 
(95%). MS (ES+, m/z) 501 [M + H]+. Anal. Calcd for C28H34Cl2N2O2: C 67.06, H 6.83; 
found, C 66.79, H 6.55.
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dimethylchrome-no[4,3-c]pyrazole (20): The title compound was prepared from 9 and 
iodomethane. Column chromatography on silica gel (hexane/EtOAc, 1:1) afforded 20 as an 
orange oil (12 mg, 50%). 1H NMR (300 MHz, CDCl3) δ: 7.51 (s, 1H, 3-H), 7.47 (d, J = 2.0 
Hz, 1H, 3-HPh), 7.35 (dd, J = 2.0 Hz, J = 8.1 Hz, 1H, 5-HPh), 7.38 (d, J = 8.1 Hz, 1H, 6-
HPh), 6.60 (d, J = 1.7 Hz, 1H, 6-H), 6.28 (d, J = 1.7 Hz, 1H, 8-H), 3.21 (s, 3H, OCH3), 1.59 
(s, 6H, OC(CH3)2), 1.52–1.46 (m, 2H, 2′-H), 1.30 (s, 6H, C(CH3)2), 1.19–1.07 (m, 6H, 3′-
H, 4′-H, 5′-H), 1.07–1.02 (br s, 2H, 6′-H), 0.79 ppm (t, J = 7.0 Hz, 3H, 7′-H). 13C NMR 
(75 MHz, CDCl3) δ: 157.0 (9-C), 156.3 (5a-C), 155.8 (7-C), 141.7 (1-CPh), 136.1 (2-CPh), 
135.5 (4-CPh), 133.9 (3-C), 131.2 (9b-C), 130.8 (3-CPh), 129.7 (5-CPh), 128.3 (6-CPh), 122.9 
(3a-C), 109.7 (6-C), 105.2 (8-C), 103.1 (9a-C), 77.4 (OC(CH3)2), 56.0 (OCH3), 43.6 (2′-C), 
38.5 (C(CH3)2), 33.1, 31.7, 26.4 (3′-C, 4′-C, 5′-C), 29.2 (C(CH3)2), 27.9 (OC(CH3)2), 24.3 
(6′-C), 13.9 ppm (7′-C). HPLC-MS: [A, 80% → 95%]. tR: 9.17 min (98%). MS (ES+, m/z) 
501 [M + H]+. Anal. Calcd for C28H34Cl2N2O2: C 67.06, H 6.83; found, C 66.85, H 7.02.
1-(3,4-Dichlorophenyl)-7-(1,1-dimethylheptyl)-9-ethoxy-1,4-dihydro-4,4-
dimethylchrome-no[4,3-c]pyrazole (21): The title compound was prepared from 8 and 
iodoethane. Column chromatography on silica gel (hexane/EtOAc, 3:1) afforded 21 as a 
yellow oil (8 mg, 39%). 1H NMR (300 MHz, CDCl3) δ: 7.75 (d, J = 1.5 Hz, 1H, 2-HPh), 
7.63 (s, 1H, 3-H), 7.41 (d, J = 7.2 Hz, 1H, 5-HPh), 7.29 (dd, J = 7.2 Hz, J = 1.5 Hz, 1H, 6-
HPh), 6.60 (d, J = 1.6 Hz, 1H, 6-H), 6.41 (d, J = 1.6 Hz, 1H, 8-H), 3.72 (q, J = 7.3 Hz, 2H, 
OCH2CH3), 1.67 (s, 6H, OC(CH3)2), 1.55–1.49 (m, 2H, 2′-H), 1.34 (s, 6H, C(CH3)2), 1.29–
1.20 (m, 6H, 3′-H, 4′-H, 5′-H), 1.16–1.13 (br s, 2H, 6′-H), 1.01 (t, J = 7.3 Hz, 3H, 
OCH2CH3), 0.85 ppm (t, J = 6.9 Hz, 3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 155.4 (9-C), 
154.7 (5a-C), 153.5 (7-C), 142.9 (1-CPh), 134.6 (3-C), 133.1 (3-CPh), 131.8 (9b-C), 130.6 
(4-CPh), 127.1 (5-CPh), 126.6 (2-CPh), 123.1 (6-CPh), 110.2 (6-C), 106.4 (8-C), 105.8 (9a-
C), 76.0 (OC(CH3)2),63.2 (OCH3), 44.7 (2′-C), 39.8 (C(CH3)2), 33.7, 32.0, 27.5 (3′-C, 4′-
C, 5′-C), 30.6 (C(CH3)2), 28.2 (OC(CH3)2, 23.0 (6′-C), 14.2 (OCH2CH3), 13.9 ppm (7′-C). 
HPLC-MS: [iso 95%–5%]. tR: 5.57 min (95%). MS (ES+, m/z) 515 [M + H]+. Anal. Calcd 
for C29H36Cl2N2O2 : C 67.57, H 7.04; found, C 67.23, H 6.89.
9-Benzyloxy-2,4-dihydro-7 - (1,1-di m ethylheptyl)-4,4 - dimethylchromeno[4,3-
c]pyrazole (22): The title compound was prepared from 5 and benzyl bromide. Column 
chromatography on silica gel (hexane/EtOAc, 3:1) afforded 22 as a yellow solid (5 mg, 
41%). mp: 110–112 °C. 1H NMR (300 MHz, CDCl3) δ: 7.55–7.29 (m, 5H, 2-HBn, 3-HBn, 4-
HBn, 5-HBn, 6-HBn), 7.16 (s, 1H, 3-H), 6.62 (d, J = 1.5 Hz, 1H, 6-H), 6.57 (d, J = 1.5 Hz, 
1H, 8-H), 5.18 (s, 2H, OCH2), 1.64 (s, 6H, OC(CH3)2), 1.58–1.48 (m, 2H, 2′-H), 1.25 (s, 
6H, C(CH3)2), 1.22–1.12 (m, 6H, 3′-H, 4′-H, 5′-H), 1.12–0.96 (m, 2H, 6′-H), 0.90–0.79 
ppm (m, 3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 157.0 (9-C), 155.2 (5a-C), 153.7 (7-C), 
142.5 (9b-C), 139.6 (1-CBn), 134.8 (3-C), 129.3, 128.1, 127.5 (2-CBn, 3-CBn, 4-CBn, 5-CBn, 
6-CBn), 124.3 (3a-C), 111.4 (6-C), 108.6 (8-C), 106.3 (9a-C), 75.7 (OC(CH3)2), 71.3 
(OCH2), 43.1 (2′-C), 39.4 (C(CH3)2), 32.8, 30.6, 25.8 (3′-C, 4′-C, 5′-C), 28.2 (C(CH3)2), 
27.3 (OC(CH3)2), 23.9 (6′-C), 15.1 ppm (7′-C); ppm (7′-C). HPLC-MS: [iso 95%–5%]. tR: 
2.25 min (95%). MS (ES+, m/z) 433 [M + H]+. Anal. Calcd for C28H36N2O2: C 77.74, H 
8.39; found, C 77.92, H, 8.16.
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9-Benzyloxy-7-(1 ,1 -d imethylhep tyl)-2 ,4-dihydro-2,4 ,4 - trimethylchromeno[4,3-
c]pyrazole (23): The title compound was prepared from 6b and benzyl bromide. Column 
chromatography on silica gel (hexane/EtOAc, 2:1) afforded 23 as a pale yellow oil (12 mg, 
96%). 1H NMR (300 MHz, CDCl3) δ: 7.71 (d, J = 7.0 Hz, 2H, 2-HBn, 6-HBn), 7.41–7.36 (m, 
2H, 3-HBn, 5-HBn), 7.31–7.26 (m, 1H, 4-HBn), 7.11 (s, 1H, 3-H), 6.58 (d, J = 1.3 Hz, 1H, 6-
H), 6.50 (d, J = 1.3 Hz, 1H, 8-H), 5.92 (s, 2H, OCH2), 3.98 (s, 3H, NCH3), 1.56 (s, 6H, 
OC(CH3)2), 1.50–1.44 (m, 2H, 2′-H), 1.22 (s, 6H, C(CH3)2), 1.16–1.11 (m, 6H, 3′-H, 4′-H, 
5′-H), 1.05–0.99 (br s, 2H, 6′-H), 0.81 ppm (t, J = 8.0 Hz, 3H, 7′-H). 13C NMR (75 MHz, 
CDCl3) δ: 154.3 (9-C), 153.8 (5a-C), 151.2 (7-C), 141.0 (9b-C), 137.8 (1-CBn), 128.1 (3-
CBn, 5-CBn), 127.1 (4-CBn), 126.9 (2-CBn, 6-CBn), 123.2 (3-C), 122.1 (3a-C), 108.9 (6-C), 
105.7 (8-C), 104.9 (9a-C), 75.5 (OC(CH3)2), 70.6 (OCH2), 44.5 (NCH3), 39.0 (2′-C), 37.9 
(C(CH3)2), 31.7, 29.8, 24.5 (3′-C, 4′-C, 5′-C), 28.9 (C(CH3)2), 28.7 (OC(CH3)2), 22.5 (6′-
C), 14.0 ppm (7′-C). HPLC-MS: [iso 95%–5%]. tR: 2.47 min (99%). MS (ES+, m/z) 447 [M 
+ H]+. Anal. Calcd for C29H38N2O2: C 77.99, H 8.58; found, C 77.65, H, 8.81.
9-Benzyloxy-7-(1,1-dimethylheptyl)-1-ethyl-1,4-dihydro-4,4-dimethylchromeno[4,3-
c]pyrazo-le (24): The title compound was prepared from 7a and benzyl bromide. Column 
chromatography on silica gel (hexane/EtOAc, 2:1) afforded 24 as a yellow oil (14 mg, 
70%). 1H NMR (300 MHz, CDCl3) δ: 7.78 (d, J = 7.1 Hz, 2H, 2-HBn, 6-HBn), 7.49–7.45 (m, 
2H, 3-HBn, 5-HBn), 7.38–7.33 (m, 1H, 4-HBn), 7.30 (s, 1H, 3-H), 6.58 (d, J = 1.9 Hz, 1H, 6-
H), 6.50 (d, J = 1.9 Hz, 1H, 8-H), 5.45 (s, 2H, OCH2), 4.38 (q, J = 7.5 Hz, 2H, NCH2CH3), 
1.63 (s, 6H, OC(CH3)2), 1.59–1.55 (br s, 2H, 2′-H), 1.49 (t, 3H, J = 7.5 Hz, NCH2CH3), 
1.29 (s, 6H, C(CH3)2), 1.22–1.13 (m, 6H, 3′-H, 4′-H, 5′-H), 1.10–1.02 (m, 2H, 6′-H), 0.90 
ppm (t, J = 6.7 Hz, 3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 152.5 (9-C), 151.9 (5a-C), 
150.6 (7-C), 141.0 (9b-C), 138.5 (1-CBn), 129.2 (3-CBn, 5-CBn), 127.0 (4-CBn), 125.3 (2-
CBn, 6-CBn), 123.1 (3-C), 121.9 (3a-C), 108.1 (6-C), 106.5 (8-C), 103.9 (9a-C), 74.9 
(OC(CH3)2), 71.5 (OCH2), 48.3 (NCH2CH3), 45.8 (2′-C), 39.4 (C(CH3)2), 32.1, 30.8, 25.6 
(3′-C, 4′-C, 5′-C), 29.3 (C(CH3)2), 28.1 (OC(CH3)2), 23.0 (6′-C), 14.9 (NCH2CH3), 13.7 
ppm (7′-C). HPLC-MS: [iso 95%–5%]. tR: 3.28 min (96%). MS (ES+, m/z) 461 [M + H]+. 
Anal. Calcd for C30H40N2O2: C 78.22, H 8.75; found, C 77.98, H 9.06.
9-Benzyloxy-7-(1,1-dimethylheptyl)-2-ethyl-2,4-dihydro-4,4-dimethylchromeno[4,3-
c]pyrazo-le (25): The title compound was prepared from 7b and benzyl bromide. Column 
chromatography on silica gel (hexane/EtOAc, 3:1) afforded 25 as a white oil (14 mg, 
81%). 1H NMR (300 MHz, CDCl3) δ: 7.76 (d, J = 7.1 Hz, 2H, 2-HBn, 6-HBn), 7.40–7.37 (m, 
2H, 3-HBn, 5-HBn), 7.32–7.27 (m, 1H, 4-HBn), 7.15 (s, 1H, 3-H), 6.60 (d, J = 1.7 Hz, 1H, 6-
H), 6.59 (d, J = 1.7 Hz, 1H, 8-H), 5.28 (s, 2H, OCH2), 4.24 (q, J = 7.3 Hz, 2H, NCH2CH3), 
1.63–1.58 (m, 11H, OC(CH3)2, 2′-H, NCH2CH3), 1.25 (s, 6H, C(CH3)2), 1.20–1.07 (m, 6H, 
3′-H, 4′-H, 5′-H), 1.08–0.91 (m, 2H, 6′-H), 0.83 ppm (t, J = 6.9 Hz, 3H, 7′-H). 13C NMR 
(75 MHz, CDCl3) δ: 154.4 (9-C), 153.8 (5a-C), 151.1 (7-C), 140.8 (9b-C), 137.9 (1-CBn), 
128.1 (3-CBn, 5-CBn), 127.1 (4-CBn), 126.9 (2-CBn, 6-CBn), 121.7 (3-C), 121.0 (3a-C), 109.0 
(6-C), 105.9 (8-C), 104.7 (9a-C), 75.6 (OC(CH3)2), 70.5 (OCH2), 47.1 (NCH2CH3), 44.6 
(2′-C), 38.0 (C(CH3)2), 31.7, 29.9, 24.6 (3′-C, 4′-C, 5′-C), 28.9 (C(CH3)2), 27.8 
(OC(CH3)2), 22.6 (6′-C), 15.4 (NCH2CH3), 14.1 ppm (7′-C). HPLC-MS: [iso 95%–5%]. 
Morales et al. Page 16













tR: 2.67 min (99%). MS (ES+, m/z) 461 [M + H]+. Anal. Calcd for C30H40N2O2: C 78.22, H 
8.75; found, C 78.50, H 8.97.
9-Benzyoxy-1-(3,4-dichlorophenyl)-7-(1,1-dimethylheptyl)-1,4-dihydro-4,4-
dimethylchrome-no[4,3-c]pyrazole (26): The title compound was prepared from 8 and 
benzyl bromide. Column chromatography on silica gel (hexane/EtOAc, 3:1) afforded 26 as a 
pale yellow oil (13 mg, 75%). 1H NMR (300 MHz, CDCl3) δ: 7.44 (s, 1H, 3-H), 7.32–7.19 
and 7.12–6.95 (m and m, 4H and 4H, 2-HBn, 3-HBn, 4-HBn, 5-HBn, 6-HBn, 2-HPh, 5-HPh, 6-
HPh), 6.66 (d, J = 1.6 Hz, 1H, 6-H), 6.44 (d, J = 1.6 Hz, 1H, 8-H), 4.53 (s, 2H, OCH2), 1.55 
(s, 8H, OC(CH3)2, 2′-H), 1.20 (s, 6H, C(CH3)2), 1.14–1.10 (m, 6H, 3′-H, 4′-H, 5′-H), 
1.07–0.88 (m, 2H, 6′-H), 0.83–0.72 ppm (m, 3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 
154.0 (9-C), 153.3 (5a-C), 152.9 (7-C), 142.0 (9b-C), 135.5 (3-C), 134.9, 132.5, 131.7, 
130.2, 129.4, 128.4, 128.2, 128.0, 127.8, 127.6, 127.4, 125.2 (1-CBn, 2-CBn, 3-CBn, 4-CBn, 
5-CBn, 6-CBn, 1-CPh, 2-CPh, 3-CPh, 4-CPh, 5-CPh, 6-CPh), 124.7 (3a-C), 122.2 (9a-C), 109.6 
(6-C), 103.6 (8-C), 76.2 (OC(CH3)2), 70.0 (OCH2), 44.4 (2′-C), 38.2 (C(CH3)2), 31.7, 29.9, 
24.6 (3′-C, 4′-C, 5′-C), 28.7(C(CH3)2), 27.2 (OC(CH3)2), 22.6 (6′-C), 14.1 ppm (7′-C). 
HPLC-MS: [iso 95%–5%]. tR: 6.44 min (94%). MS (ES+, m/z) 577 [M + H]+. Anal. Calcd 
for C34H38Cl2N2O2: C 70.70, H 6.63; found, C 70.82, H 6.57.
9-Benzyloxy-1-(2,4-dichlorophenyl)-7-(1,1-dimethylheptyl)-1,4-dihydro-4,4-dimethyl-9-
methoxychromeno[4,3-c]pyrazole (27): The title compound was prepared from 9 and 
benzyl bromide. Column chromatography on silica gel (hexane/EtOAc, 3:1) afforded 27 as 
an orange oil (13 mg, 61%). 1H NMR (300 MHz, CDCl3) δ: 7.55 (s, 1H, 3-H), 7.36–7.27 
(m, 4H, 2-HBn, 3-HBn, 5-HBn, 6-HBn), 7.15 (d, J = 2.3 Hz, 1H, 3-HPh), 7.13–7.02 (m, 2H, 6-
HPh, 4-HBn), 6.97 (dd, J = 8.5, 2.3 Hz, 1H, 5-HPh), 6.65 (d, J = 1.6 Hz, 1H, 6-H), 6.35 (d, J = 
1.6 Hz, 1H, 8-H), 4.53 (s, 2H, OCH2), 1.64 (s, 6H, OC(CH3)2), 1.52–1.36 (m, 2H, 2′-H), 
1.22 (s, 6H, C(CH3)2), 1.20–1.09 (m, 6H, 3′-H, 4′-H, 5′-H), 1.03–0.89 (m, 2H, 6′-H), 
0.88–0.79 ppm (m, 3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 154.1 (9-C), 153.7 (5a-C), 
153.3 (7-C), 140.3 (9b-C), 136.8 (3-C), 135.2, 134.8, 133.9, 131.7, 131.7, 129.8, 128.9, 
128.8, 128.5, 128.3, 127.7, 127.1 (1-CBn, 2-CBn, 3-CBn, 4-CBn, 5-CBn, 6-CBn, 1-CPh, 2-CPh, 
3-CPh, 4-CPh, 5-CPh, 6-CPh), 123.7 (9a-C), 109.7 (6-C), 104.2 (8-C), 77.6 (OC(CH3)2), 70.6 
(OCH2), 44.8 (2′-C), 38.5 (C(CH3)2), 32.1, 30.2, 24.9 (3′-C, 4′-C, 5′-C), 29.1 (C(CH3)2), 
27.9 (OC(CH3)2), 23.0 (6′-C), 14.5 ppm (7′-C). HPLC-MS: [iso 95%–5%]. tR: 4.12 min 
(94%). MS (ES+, m/z) 577 [M + H]+. Anal. Calcd for C34H38Cl2N2O2: C 70.70, H 6.63; 
found, C 70.95, H 6.49.
7-(1,1-Dimethylheptyl)-2,4-dihydro-9-(3-hydroxypropoxy)-4,4-dimethylchromeno[4,3-
c]pyrazole (28): The title compound was prepared from 5 and 3-bromo-1-propanol. Column 
chromatography on silica gel (hexane/EtOAc, 1:1) afforded 28 as a white solid (55 mg, 
47%). mp: 82–84 °C. 1H NMR (300 MHz, CDCl3) δ: 8.28–8.21 (br s, 1H, NH), 7.18 (s, 1H, 
3-H), 6.58 (d, J = 1.6 Hz, 1H, 6-H), 6.49 (d, J = 1.6 Hz, 1H, 8-H), 4.29 (t, J = 6.5 Hz, 2H, 
OCH2CH2CH2OH), 3.67 (t, J = 6.3 Hz, 2H, OCH2CH2CH2OH), 2.13 (p, J = 6.3 Hz, 2H, 
OCH2CH2CH2OH), 1.61 (s, 6H, OC(CH3)2), 1.59–1.45 (m, 2H, 2′-H), 1.25 (s, 6H, 
C(CH3)2), 1.22–1.12 (m, 8H, 3′-H, 4′-H, 5′-H, 6′-H), 0.83 ppm (t, J = 6.7 Hz, 3H, 7′-
H). 13C NMR (75 MHz, CDCl3) δ: 153.8 (9-C), 153.2 (5a-C), 152.9 (7-C), 142.5 (9b-C), 
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123.8 (3-C), 120.0 (3a-C), 106.6 (6-C), 106.4 (8-C), 101.1 (9a-C), 76.6 (OC(CH3)2), 59.3 
(OCH2CH2CH2OH), 48.8 (OCH2CH2CH2OH), 44.5 (2′-C), 38.0 (C(CH3)2), 32.7 
(OCH2CH2CH2OH), 31.8, 30.0, 24.6, 22.6 (3′-C, 4′-C, 5′-C, 6′-C), 29.7 (C(CH3)2), 28.9 
(OC-(CH3)2), 14.1 ppm (7′-C). HPLC-MS: [A, 80% → 95%]. tR: 3.85 min (97%). MS 
(ES+, m/z) 401 [M + H]+. Anal. Calcd for C24H36N2O3: C 71.96, H 9.06; found, C 72.23, H, 
9.10.
7-(1,1-Dimethylheptyl)-2,4-dihydro-9-(3-hydroxypropoxy)-2,4,4-
trimethylchromeno[4,3-c]pyrazole (29): The title compound was prepared from 6b and 3-
bromo-1-propanol. Column chromatography on silica gel (hexane/EtOAc, 1:1) afforded 29 
as a pale orange oil (20 mg, 59%). 1H NMR (300 MHz, CDCl3) δ: 7.01 (s, 1H, 3-H), 6.52 
(d, J = 1.6 Hz, 1H, 6-H), 6.45 (d, J = 1.6 Hz, 1H, 8-H), 4.18 (t, J = 6.5 Hz, 2H, 
OCH2CH2CH2OH), 4.01 (s, 3H, NCH3), 3.86–3.80 (m, 2H, OCH2CH2CH2OH), 2.13–1.96 
(m, 2H, OCH2CH2CH2OH), 1.52 (s, 6H, OC(CH3)2), 1.42–1.38 (m, 2H, 2′-H), 1.19 (s, 6H, 
C(CH3)2), 1.16–0.92 (m, 8H, 3′-H, 4′-H, 5′-H, 6′-H), 0.77 ppm (t, J = 6.6 Hz, 3H, 7′-
H). 13C NMR (75 MHz, CDCl3) δ: 153.6 (9-C), 152.7 (5a-C), 150.8 (7-C), 139.5 (9b-C), 
122.6 (3-C), 120.5 (3a-C), 109.2 (6-C), 107 .6 (8-C), 101.3 ( 9a-C), 74.8 ( O C (C H 3 ) 2 ), 
59.5 (OCH2CH2CH2OH), 50.1 (OCH2CH2CH2OH), 45.3 (NCH3), 39.5 (2′-C), 37.6 
(C(CH3)2), 32.8 (OCH2CH2CH2OH), 31.5, 30.9, 24.6, 22.6 (3′-C, 4′-C, 5′-C, 6′-C), 29.4 
(C(CH3)2), 28.9 (OC(CH3)2), 13.0 ppm (7′-C). HPLC-MS: [A, 80% → 95%]. tR: 4.07 min 
(93%). MS (ES+, m/z) 415 [M + H]+. Anal. Calcd for C25H38N2O2: C 72.43, H 9.24; found, 
C 72.12, H 8.98.
7-(1,1-Dimethylheptyl)-1-ethyl-1,4-dihydro-9-(3-hydroxypropoxy)-4,4-
dimethylchromeno[4,3-c]pyrazole (30): The title compound was prepared from 7a and 3-
bromo-1-propanol. Column chromatography on silica gel (hexane/EtOAc, 1:1) afforded 30 
as a yellow solid (31 mg, 48%). mp: 91–93 °C. 1H NMR (300 MHz, CDCl3) δ: 7.37 (s, 1H, 
3-H), 6.60 (d, J = 1.8 Hz, 1H, 6-H), 6.57 (d, J = 1.8 Hz, 1H, 8-H), 4.40–4.33 (m, 2H, 
OCH2CH2CH2OH), 4.07–3.89 (m, 2H, NCH2CH3), 3.62–3.51 (m, 2H, OCH2CH2CH2OH), 
2.11 (p, J = 6.4 Hz, 2H, OCH2CH2CH2OH), 1.55 (s, 6H, OC(CH3)2), 1.50 (t, J = 7.0 Hz, 
3H, NCH2CH3), 1.41–1.36 (m, 2H, 2′-H), 1.24 (s, 6H, C(CH3)2), 1.12–0.98 (m, 8H, 3′-H, 
4′-H, 5′-H, 6′-H), 0.85 ppm (t, J = 6.6 Hz, 3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 154.8 
(9-C), 153.5 (5a-C), 151.6 (7-C), 141.4 (9b-C), 131.6 (3-C), 124.5 (3a-C), 110.3 (6-C), 
107.9 (8-C), 102.6 (9a-C), 75 .0 (OC(CH3)2), 63 .2 (OCH2CH2CH2OH), 57 .6 
(OCH2CH2CH2OH), 46.5 (NCH2CH3), 44.7 (2′-C), 38.0 (C(CH3)2), 32.6 
(OCH2CH2CH2OH), 30.9, 29.6, 24.5, 21.7 (3′-C, 4′-C, 5′-C, 6′-C), 29.2 (C(CH3)2), 28.1 
(OC(CH3)2), 15.0 (NCH2CH3), 14.1 ppm (7′-C). HPLC-MS: [A, 80% → 95%]. tR: 3.42 
min (99%). MS (ES+, m/z) 429 [M + H]+. Anal. Calcd for C26H40N2O3: C 72.86, H 9.41; 
found, C 72.75, H 9.63.
7-(1,1-Dimethylheptyl)-2-ethyl-2,4-dihydro-9-(3-hydroxypropoxy)-4,4-
dimethylchromeno-[4,3-c]pyrazole (31): The title compound was prepared from 7b and 3-
bromo-1-propanol. Column chromatography on silica gel (hexane/EtOAc, 1:1) afforded 31 
as a yellow gummy solid (22 mg, 76%). 1H NMR (300 MHz, CDCl3) δ: 7.13 (s, 1H, 3-H), 
6.58 (d, J = 1.6 Hz, 1H, 6-H), 6.52 (d, J = 1.6 Hz, 1H, 8-H), 4.31–4.25 (m, 2H, 
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OCH2CH2CH2OH), 4.09–3.98 (m, 2H, NCH2CH3), 3.66–3.45 (m, 2H, OCH2CH2CH2OH), 
2.14–2.10 (m, 2H, OCH2CH2CH2OH), 1.59 (s, 6H, OC(CH3)2), 1.51 (t, J = 7.2 Hz, 3H, 
NCH2CH3), 1.46–1.42 (m, 2H, 2′-H), 1.26 (s, 6H, C(CH3)2), 1.22–0.96 (m, 8H, 3′-H, 4′-H, 
5′-H, 6′-H), 0.87–0.79 ppm (m, 3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 153.5 (9-C), 
152.8 (5a-C), 150.9 (7-C), 139.2 (9b-C), 120.8 (3-C), 120.3 (3a-C), 109.0 (6-C), 107.6 (8-
C), 101.3 (9a-C), 74.8 (OC(CH3)2), 65.3 (OCH2CH2CH2OH), 60.8 (OCH2CH2CH2OH), 
46.0 (NCH2CH3), 43.5 (2′-C), 37.1 (C(CH3)2), 31.5 (OCH2CH2CH2OH), 30.7, 28.9, 23.6, 
21.6 (3′-C, 4′-C, 5′-C, 6′-C), 28.1 (C(CH3)2), 27.8 (OC-(CH3)2), 14.7 (NCH2CH3), 13.0 
ppm (7′-C). HPLC-MS: [A, 80% → 95%]. tR: 4.63 min (96%). MS (ES+, m/z) 429 [M + 
H]+. Anal. Calcd for C26H40N2O3: C 72.86, H 9.41; found, C 72.88, H 9.19.
1-(3,4-Dichlorophenyl)-7-(1,1-dimethylheptyl)-1,4-dihydro-9-(3-hydroxypropoxy)-4,4-
dime-thylchromeno[4,3-c]pyrazole (32): The title compound was prepared from 8 and 3-
bromo-1-propanol. Column chromatography on silica gel (hexane/EtOAc, 1:1) afforded 32 
as a yellow oil (9 mg, 40%). 1H NMR (300 MHz, CDCl3) δ: 7.97 (d, J = 2.5 Hz, 1H, 2-HPh), 
7.71 (dd, J = 7.8, 2.5 Hz, 1H, 6-HPh), 7.49 (d, J = 7.8 Hz, 1H, 5-HPh), 7.47 (s, 1H, 3-H), 6.62 
(d, J = 1.7 Hz, 1H, 6-H), 6.60 (d, J = 1.7 Hz, 1H, 8-H), 4.12 (t, J = 6.2 Hz, 2H, 
OCH2CH2CH2OH), 3.88 (t, J = 6.2 Hz, 2H, OCH2CH2CH2OH), 2.09 (p, J = 6.2 Hz, 2H, 
OCH2CH2CH2OH), 1.65 (s, 6H, OC(CH3)2), 1.60–1.40 (m, 2H, 2′-H), 1.22 (s, 6H, 
C(CH3)2), 1.20–0.94 (m, 8H, 3′-H, 4′-H, 5′-H, 6′-H), 0.83–0.72 ppm (m, 3H, 7′-H). 13C 
NMR (75 MHz, CDCl3) δ: 155.2 (9-C), 153.9 (5a-C), 152.5 (7-C), 140.7 (1-CPh), 139.7 (9b-
C), 136.0 (3-CPh), 130.3 (3-C), 129.6 (4-CPh), 127.4 (5-CPh), 125.3 (2-CPh), 124.1 (6-CPh), 
121.6 (3a-C), 110.7 (6-C), 108.5 (8-C), 102.3 (9a-C), 75.1 (OC(CH3)2), 67.9 
(OCH2CH2CH2OH), 62.1 (OCH2CH2CH2OH), 44.6 (2′-C), 38.2 (C(CH3)2), 31.7 
(OCH2CH2CH2OH), 30.9, 29.1, 24.0, 21.3 (3′-C, 4′-C, 5′-C, 6′-C), 28.6 (C(CH3)2), 27.9 
(OC(CH3)2), 14.3 ppm (7′-C). HPLC-MS: [A, 80% → 95%]. tR: 4.58 min (93%). MS 
(ES+, m/z) 545 [M + H]+. Anal. Calcd for C30H38Cl2N2O3: C 66.05, H 7.02; found, C 
65.81, H 7.13.
1-(2,4-Dichlorophenyl)-7-(1,1-dimethylheptyl)-1,4-dihydro-9-(3-hydroxypropoxy)-4,4-
dime-thyl-9-methoxychromeno[4,3-c]-pyrazole (33): The title compound was prepared 
from 9 and 3-bromo-1-propanol. Column chromatography on silica gel (hexane/EtOAc, 1:1) 
afforded 33 as a yellow gummy solid (18 mg, 31%). 1H NMR (300 MHz, CDCl3) δ: 7.57 (s, 
1H, 3-H), 7.51 (d, J = 1.8 Hz, 1H, 3-HPh), 7.25–7 0.18 (m, 2H, 5-HPh, 6-HPh), 6.66 (d, J = 
1.6 Hz, 1H, 6-H), 6.40 (d, J = 1.6 Hz, 1H, 8-H), 3.82–3.60 (m, 2H, OCH2CH2CH2OH), 3.56 
(t, J = 6.0 Hz, 2H, OCH2CH2CH2OH), 1.90–1.85 (m, 2H, OCH2CH2CH2OH), 1.63 (s, 6H, 
OC(CH3)2), 1.57–1.46 (m, 2H, 2′-H), 1.24 (s, 6H, C(CH3)2), 1.22–0.96 (m, 8H, 3′-H, 4′-H, 
5′-H, 6′-H), 0.84 ppm (t, J = 6.6 Hz, 3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 153.6 (9-
C), 153.3 (5a-C), 153.2 (7-C), 140.0 (1-CPh), 134.8 (9b-C), 134.4 (2-CPh), 133.5 (4-CPh), 
131.1 (3-C), 129.6 (3-CPh), 128.6 (5-CPh), 127.0 (6-CPh), 123.5 (3a-C), 109.1 (6-C), 103.7 
(8-C), 103.0 (9a-C), 76.5 (OC(CH3 )2 ), 64.9 (OCH2CH2CH2OH), 59.4 
(OCH2CH2CH2OH), 44.3 (2′-C), 38.1 (C(CH3)2), 31.6 (OCH2CH2CH2OH), 31.0, 29.8, 
24.5, 22.5 (3′-C, 4′-C, 5′-C, 6′-C), 28.5 (C(CH3)2), 27.3 (C(CH3)2), 14.0 ppm (7′-C). 
HPLC-MS: [A, 80% → 95%]. tR: 4.72 min (96%). MS (ES+, m/z) 545 [M + H]+. Anal. 
Calcd for C30H38Cl2N2O3: C 66.05, H 7.02; found, C 66.26, H 6.97.
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c]pyra-zole (34): The title compound was prepared from 5 and 2-bromoetanol. Column 
chromatography on silica gel (hexane/EtOAc, 1:1) afforded the title compound as a white 
solid (12 mg, 54%). mp: 85–87 °C. 1H NMR (300 MHz, CDCl3) δ: 7.34 (s, 1H, 3-H), 6.60 
(d, J = 1.7 Hz, 1H, 6-H), 6.52 (d, J = 1.7 Hz, 1H, 8-H), 4.19–4.07 (m, 2H, OCH2CH2OH), 
3.56–3.45 (m, 2H, OCH2CH2OH), 1.64 (s, 6H, OC(CH3)2), 1.60–1.48 (m, 2H, 2′-H), 1.25 
(s, 6H, C(CH3)2), 1.23–0.97 (m, 8H, 3′-H, 4′-H, 5′-H, 6′-H), 0.88–0.79 ppm (m, 3H, 7′-
H). 13C NMR (75 MHz, CDCl3) δ: 155.2 (9-C), 154.1 (5a-C), 152.6 (7-C), 141.3 (9b-C), 
124.9 (3-C), 121.9 (3a-C), 109.3 (6-C), 106.6 (8-C), 102.7 (9a-C), 74.8 (OC(CH3)2), 60.1 
(OCH2CH2OH), 51.4 (OCH2CH2OH), 43.2 (2′-C), 37.7 (C(CH3)2), 32.0, 31.4, 25.7, 22.3 
(3′-C, 4′-C, 5′-C, 6′-C), 29.8 (C(CH3)2), 27.9 (OC(CH3)2), 15.0 ppm (7′-C). HPLC-MS: 
[A, 80% → 95%]. tR: 3.45 min (93%). MS (ES+, m/z) 387 [M + H]+. Anal. Calcd for 
C23H34N2O3: C 71.47, H 8.87; found, C 71.80, H, 8.64.
7-(1,1-Dimethylheptyl)-2,4-dihydro-9-(2-hydroxyethoxy)-2,4,4-trimethylchromeno[4,3-
c]py-razole (35): The title compound was prepared from 6b and 2-bromoetanol. Column 
chromatography on silica gel (hexane/EtOAc, 1:2) afforded 35 as a pale yellow oil (16 mg, 
73%). 1H NMR (300 MHz, CDCl3) δ: 7.19 (s, 1H, 3-H), 6.59 (d, J = 1.8 Hz, 1H, 6-H), 6.51 
(d, J = 1.8 Hz, 1H, 8-H), 4.30–4.25 (m, 2H, OCH2CH2OH), 4.05 (s, 3H, NCH3), 3.81–3.74 
(m, 2H, OCH2CH2OH), 1.60 (s, 6H, OC(CH3)2), 1.40–1.35 (m, 2H, 2′-H), 1.21 (s, 6H, 
C(CH3)2), 1.12–0.89 (m, 8H, 3′-H, 4′-H, 5′-H, 6′-H), 0.81 ppm (t, J = 6.9 Hz, 3H, 7′-
H). 13C NMR (75 MHz, CDCl3) δ: 154.1 (9-C), 153.5 (5a-C), 152.3 (7-C), 140.5 (9b-C), 
123.8 (3-C), 121.4 (3a-C), 111.2 (6-C), 108.5 (8-C), 103.6 (9a-C), 76.0 (OC(CH3)2), 64.3 
(OCH2CH2OH), 59.2 (OCH2CH2OH), 40.6 (NCH3), 39.0 (2′-C), 38.1 (C(CH3)2), 32.1, 
30.8, 25.7, 21.3 (3′-C, 4′-C, 5′-C, 6′-C), 29.7 (C(CH3)2), 28.0 (OC(CH3)2), 14.7 ppm (7′-
C). HPLC-MS: [A, 80% → 95%]. tR: 3.41 min (99%). MS (ES+, m/z) 401 [M + H]+. Anal. 
Calcd for C24H36N2O3: C 71.96, H 9.06; found, C 71.67, H, 8.84.
7-(1,1-Dimethylheptyl)-2-ethyl-2,4-dihydro-9-(2-hydroxyethoxy)-4,4-
dimethylchromeno[4,3-c]pyrazole (36): The title compound was prepared from 7b and 2-
bromoetanol. Column chromatography on silica gel (hexane/EtOAc, 1:1) afforded 36 as a 
white oil (13 mg, 48%). 1H NMR (300 MHz, CDCl3) δ: 7.22 (s, 1H, 3-H), 6.61 (d, J = 1.8 
Hz, 1H, 6-H), 6.57 (d, J = 1.8 Hz, 1H, 8-H), 4.30–4.23 (m, 2H, OCH2CH2OH), 3.95 (q, J = 
7.1 Hz, 2H, NCH2CH3), 3.63–3.59 (m, 2H, OCH2CH2OH), 1.62 (s, 6H, OC(CH3)2), 1.54 (t, 
J = 7.1 Hz, 3H, NCH2CH3), 1.40–1.33 (br s, 2H, 2′-H), 1.28 (s, 6H, C(CH3)2), 1.23–0.91 
(m, 8H, 3′-H, 4′-H, 5′-H, 6′-H), 0.88–0.81 ppm (m, 3H, 7′-H). 13C NMR (75 MHz, 
CDCl3) δ: 155.2 (9-C), 153.7 (5a-C), 151.8 (7-C), 140.3 (9b-C), 124.6 (3-C), 121.5 (3a-C), 
110.2 (6-C), 108.6 (8-C), 102.4 (9a-C), 75.1 (OC(CH3)2), 68.5 (OCH2CH2OH), 61.3 
(OCH2CH2OH), 47.3 (NCH2CH3), 42.9 (2′-C), 37.7 (C(CH3)2), 31.7, 30.2, 25.3, 22.5 (3′-
C, 4′-C, 5′-C, 6′-C), 29.2 (C(CH3)2), 28.3 (OC(CH3)2), 15.2 (NCH2CH3), 14.3 ppm (7′-C). 
HPLC-MS: [A, 80% → 95%]. tR: 5.22 min (92%). MS (ES+, m/z) 415 [M + H]+. Anal. 
Calcd for C25H38N2O3: C 72.43, H 9.24; found, C 72.60, H 9.08.
9-(3-Bromopropoxy)-7-(1,1-dimethylheptyl)-2,4-dihydro-2,4,4-trimethylchromeno[4,3-
c]py-razole (37): The title compound was prepared from 6b and 1,3-dibromopropane. 
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Column chromatography on silica gel (hexane/EtOAc, 3:1) afforded 37 as a white solid (27 
mg, 47%). mp: 96–98 °C. 1H NMR (300 MHz, CDCl3) δ: 7.49 (s, 1H, 3-H), 6.73 (d, J = 1.8 
Hz, 1H, 6-H), 6.68 (d, J = 1.8 Hz, 1H, 8-H), 4.34 (t, J = 6.3 Hz, 2H, OCH2CH2CH2Br), 4.07 
(s, 3H, NCH3), 3.87 (t, J = 6.3 Hz, 2H, OCH2CH2CH2Br), 2.49 (p, J = 6.3 Hz, 2H, 
OCH2CH2CH2Br), 1.60 (s, 6H, OC(CH3)2), 1.58–1.46 (m, 2H, 2′-H), 1.27 (s, 6H, 
C(CH3)2), 1.24–0.94 (m, 8H, 3′-H, 4′-H, 5′-H, 6′-H), 0.90–0.77 ppm (m, 3H, 7′-H). 13C 
NMR (75 MHz, CDCl3) δ: 153.0 (9-C), 152.5 (5a-C), 151.3 (7-C), 141.0 (9b-C), 124.7 (3-
C), 121.8 (3a-C), 109.9 (6-C), 108.5 (8-C), 103.2 (9a-C), 75.1 (OC(CH3)2), 62.3 
(OCH2CH2CH2Br), 46.7 (NCH3), 38.6 (2′-C), 37.3 (C(CH3)2), 33.1 (OCH2CH2CH2Br), 
31.7 (OCH2CH2CH2Br), 30.8, 30.1, 25.6, 21.3 (3′-C, 4′-C, 5′-C, 6′-C), 29.7 (C(CH3)2), 
28.1 (OC(CH3)2), 14.0 ppm (7′-C). HPLC-MS: [A, 80% → 95%]. tR: 5.55 min (96%). MS 
(ES+, m/z) 477 [M + H]+. Anal. Calcd for C25H37BrN2O2: C 62.89, H 7.81; found, C 63.05, 
H 7.72.
9-(3-Bromopropoxy)-7-(1,1-dimethylheptyl)-2-ethyl-2,4-dihydro-4,4-
dimethylchromeno[4,3-c]pyrazole (38): The title compound was prepared from 7b and 
1,3-dibromopropane. Column chromatography on silica gel (hexane/EtOAc, 3:1) afforded 38 
as a yellow oil (15 mg, 55%). 1H NMR (300 MHz, CDCl3) δ: 7.21 (s, 1H, 3-H), 6.62 (d, J = 
1.7 Hz, 1H, 6-H), 6.56 (d, J = 1.7 Hz, 1H, 8-H), 4.29–4.16 (m, 2H, OCH2CH2CH2Br), 4.11 
(q, 2H, J = 7.0 Hz, NCH2CH3), 3.52–3.47 (m, 2H, OCH2CH2CH2Br), 2.12–2.04 (m, 2H, 
OCH2CH2CH2Br), 1.65 (s, 6H, OC(CH3)2), 1.60 (t, J = 7.0 Hz, 3H, NCH2CH3), 1.40–1.34 
(m, 2H, 2′-H), 1.29 (s, 6H, C(CH3)2), 1.23–0.98 (m, 8H, 3′-H, 4′-H, 5′-H, 6′-H), 0.86 ppm 
(t, J = 7.1 Hz, 3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 152.9 (9-C), 152.1 (5a-C), 150.3 
(7-C), 138.4 (9b-C), 121.7 (3-C), 120.1 (3a-C), 108.3 (6-C), 106.5 (8-C), 101.8 (9a-C), 75.3 
(OC(CH3)2), 65.2 (OCH2CH2CH2Br), 45.9 (NCH2CH3), 44.1 (2′-C), 38.0 (C(CH3)2), 32.7 
(OCH2CH2CH2Br), 31.9 (OCH2CH2CH2Br), 31.0, 29.8, 24.2, 21.6 (3′-C, 4′-C, 5′-C, 6′-
C), 28.7 (C(CH3)2), 27.5 (OC(CH3)2), 14.8 (NCH2CH3), 13.5 ppm (7′-C). HPLC-MS: [A, 
80% → 95%]. tR: 5.14 min (95%). MS (ES+, m/z) 491 [M + H]+. Anal. Calcd for 
C26H39BrN2O2: C 63.54, H 8.00; found, C 63.87, H 8.12.
9-(2-Bromoethoxy)-7-(1,1-dimethylheptyl)-1-ethyl-1,4-dihydro-4,4-
dimethylchromeno[4,3-c]pyrazole (39): The title compound was prepared from 7a and 
1,2-dibromoethane. Column chromatography on silica gel (hexane/EtOAc, 2:1) afforded 39 
as a yellow oil (16 mg, 64%). 1H NMR (300 MHz, CDCl3) δ: 7.29 (s, 1H, 3-H), 6.69 (d, J = 
1.5 Hz, 1H, 6-H), 6.61 (d, J = 1.5 Hz, 1H, 8-H), 4.38–4.31 (m, 2H, OCH2CH2Br), 4.03 (q, J 
= 7.5 Hz, 2H, NCH2CH3), 3.71–3.62 (m, 2H, OCH2CH2Br), 1.56 (s, 6H, OC(CH3)2), 1.53 
(t, J = 7.5 Hz, 3H, NCH2CH3), 1.50–1.42 (m, 2H, 2′-H), 1.27 (s, 6H, C(CH3)2), 1.17–1.04 
(m, 8H, 3′-H, 4′-H, 5′-H, 6′-H), 0.88 ppm (t, J = 6.6 Hz, 3H, 7′-H). 13C NMR (75 MHz, 
CDCl3) δ: 155.3 (9-C), 154.0 (5a-C), 152.5 (7-C), 142.6 (9b-C), 133.7 (3-C), 124.8 (3a-C), 
109.9 (6-C), 108.1 (8-C), 103.5 (9a-C), 76.2 (OC(CH3)2), 64.7 (OCH2CH2Br), 45.9 
(NCH2CH3), 43.8 (2′-C), 37.5 (C(CH3)2), 31.2 (OCH2CH2Br), 30.3, 29.7, 25.7, 22.3 (3′-C, 
4′-C, 5′-C, 6′-C), 29.0 (C(CH3)2), 27.7 (OC(CH3)2), 15.2 (NCH2CH3), 14.0 ppm (7′-C). 
HPLC-MS: [A, 80% → 95%]. tR: 5.64 min (95%). MS (ES+, m/z) 477 [M + H]+. Anal. 
Calcd for C25H37BrN2O2: C 62.89, H 7.81; found, C 62.61, H 8.03.
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5,6]chrome-no[4,3-c]pyrazole (40): Compound 30 (25 mg, 0.06 mmol) in 1.5 mL of dry 
toluene was added to a stirred suspension of P2O5 (16 mg, 0.12 mmol) in 2 mL of dry 
toluene under nitrogen atmosphere, and the mixture was refluxed for 1 h. After completion, 
the reaction mixture was cooled to room temperature and filtered. The filtrate was diluted 
with EtOAc and washed with NaOH (0.1 N), water, and brine and extracted three times with 
EtOAc. The combined organic layers were dried over MgSO4, and the solvent was removed 
under vacuum. Column chromatography on silica gel (hexane/EtOAc, 4:1) afforded 40 as a 
yellow oil (20 mg, 87%). 1H NMR (300 MHz, CDCl3) δ: 7.39 (s, 1H, 3-H), 6.59 (s, 1H, 6-
H), 4.41–4.32 (m, 2H, OCH2CH2CH2), 4.21–4.16 (m, 2H, NCH2CH3), 2.84–2.78 (m, 2H, 
OCH2CH2CH2), 2.09–2.01 (m, 2H, OCH2CH2CH2), 1.61 (s, 6H, OC(CH3)2), 1.56 (t, J = 
6.7 Hz, 3H, NCH2CH3), 1.45–1.40 (m, 2H, 2′-H), 1.27 (s, 6H, C(CH3)2), 1.10–0.96 (m, 8H, 
3′-H, 4′-H, 5′-H, 6′-H), 0.85–0.79 ppm (m, 3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 
153.9 (11a-C), 152.8 (5a-C), 152.0 (7-C), 142.5 (11c-C), 132.3 (3-C), 128.0 (3a-C), 109.6 
(7a-C), 108.3 (6-C), 103.5 (11b-C), 74.9 (OC(CH3)2), 63.7 (OCH2CH2CH2), 46.1 
(NCH2CH3), 43.4 (2′-C), 37.7 (C(CH3)2), 32.0, 31.3, 29.4, 24.6, 23.9, 21.2 (3′-C, 4′-C, 5′-
C, 6′-C, OCH2CH2CH2), 29.0 (C(CH3)2), 28.5 (OC(CH3)2), 15.4 (NCH2CH3), 14.1 ppm 
(7′-C). HPLC-MS: [A, 80% → 95%]. tR: 5.82 min (95%). MS (ES+, m/z) 411 [M + H]+. 
Anal. Calcd for C26H38N2O2: C 76.06, H 9.33; found, C 75.82, H 9.08.
7-(1,1-Dimethylheptyl)-2-ethyl-2,4,9,10-tetrahydro-4,4-dimethyl-8H-pyrano[2′,3′:
5,6]chrome-no[4,3-c]pyrazole (41): The title compound was prepared from 31 (71 mg, 
0.16 mmol) and P2O5 (46 mg, 0.33 mmol) following the procedure previously described for 
40. Column chromatography on silica gel (hexane/EtOAc, 4:1) afforded 41 as a pale yellow 
oil (23 mg, 52%). 1H NMR (300 MHz, CDCl3) δ: 7.20 (s, 1H, 3-H), 6.61 (s, 1H, 6-H), 4.31–
4.27 (m, 2H, OCH2CH2CH2), 4.20–4.16 (m, 2H, NCH2CH3), 2.72–2.69 (m, 2H, 
OCH2CH2CH2), 2.11–2.04 (m, 2H, OCH2CH2CH2), 1.67 (s, 6H, OC(CH3)2), 1.52 (t, J = 
7.0 Hz, 3H, NCH2CH3), 1.50–1.46 (m, 2H, 2′-H), 1.26 (s, 6H, C(CH3)2), 1.15–0.99 (m, 8H, 
3′-H, 4′-H, 5′-H, 6′-H), 0.84 ppm (t, J = 6.9 Hz, 3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 
154.0 (11a-C), 153.7 (5a-C), 152.5 (7-C), 140.9 (11c-C), 122.3 (3-C), 119.6 (3a-C), 108.8 
(7a-C), 108.1 (6-C), 104.2 (11b-C), 75.3 (OC(CH3)2), 65.0 (OCH2CH2CH2), 45.9 
(NCH2CH3), 44.1 (2′-C), 38.2 (C(CH3)2), 31.4, 30.8, 29.5, 24.9, 24.0, 22.6 (3′-C, 4′-C, 5′-
C, 6′-C, OCH2CH2CH2), 29.1 (C(CH3)2), 28.7 (OC(CH3)2), 14.9 (NCH2CH3), 13.8 ppm 
(7′-C). HPLC-MS: [A, 80% → 95%]. tR: 5.07 min (98%). MS (ES+, m/z) 411 [M + H]+. 
Anal. Calcd for C26H38N2O2: C 76.06, H 9.33; found, C 76.35, H 8.99.
7-(1,1-Dimethylheptyl)-4,4-dimethyl-4H-chromeno[3,4-d]-isoxazol-9-ol (42): A solution 
of 434 (0.12 g, 0.35 mmol) and hydroxylamine hydrochloride (49 mg, 0.71 mmol) in ethanol 
(4 mL) was refluxed for 45 min. After cooling the mixture, the crude was filtered and 
washed with cold ethanol. After removal of the solvent, the crude was purified by 
chromatography on silica gel (hexane/EtOAc, 2:1) to obtain 42 as a pale yellow solid (0.11 
g; 91%). mp: 109–111 °C. 1H NMR (300 MHz, CDCl3) δ: 8.12 (s, 1H, 3-H), 6.57 (d, J = 1.6 
Hz, 1H, 8-H), 6.55 (d, J = 1.4 Hz, 6-H), 1.64 (s, 6H, OC(CH3)2), 1.59–1.47 (m, 2H, 2′-H), 
1.24 (s, 6H, C(CH3)2), 1.17–1.09 (br s, 8H, 3′-H, 4′-H, 5′-H, 6′-H), 0.82 ppm (t, J = 7.0 
Hz, 3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 160.2 (9-C), 156.6 (9b-C), 153.6 (5a-C), 
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151.7 (7-C), 145.4 (3-C), 119.4 (9a-C), 109.5 (8-C), 108.1 (6-C), 105.9 (3a-C), 78.0 
(OC(CH3)2), 44.5 (2′-C), 38.5 (C(CH3)2), 31.9, 30.1, 24.8 (3′-C, 4′-C, 5′-C), 29.2 
(C(CH3)2), 28.9 (OC(CH3)2), 22.9 (6′-C), 14.3 ppm (7′-C). HPLC-MS: [A, 80% → 95%]. 
tR: 2.77 min (99%). MS (ES+, m/z) 344 [M + H]+. Anal. Calcd for C21H29NO3 73.44, H 
8.51; found, C 73.81, H, 8.59.
7-(1,1-Dimethylheptyl)-9-methoxy-4,4-dimethyl-4H-chromeno-[3,4-d]isoxazole 
(43): The title compound was prepared from 42 (30 mg, 0.09 mmol), sodium hydride (3 mg, 
0.13 mmol), and iodomethane (16 μL, 0.26 mmol) following the procedure described for 15. 
Column chromatography on silica gel (hexane/EtOAc, 2:1) afforded 43 as a yellow oil (19 
mg, 61%). 1H NMR (300 MHz, CDCl3) δ: 8.10 (s, 1H, 3-H), 6.47 (d, J = 1.6 Hz, 1H, 8-H), 
6.35 (d, J = 1.6 Hz, 1H, 6-H), 3.59 (s, 3H, OCH3), 1.77 (s, 6H, OC(CH3)2), 1.54–1.31 (m, 
2H, 2′-H), 1.26 (s, 6H, C(CH3)2), 1.17–0.98 (m, 8H, 3′-H, 4′-H, 5′-H, 6′-H), 0.83–0.78 
ppm (m, 3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 165.6 (9-C), 162.2 (9b-C), 157.8 (5a-C), 
153.5 (7-C), 150.1 (3-C), 118.0 (9a-C), 108.3 (8-C), 106.5 (6-C), 103.0 (3a-C), 76.7 
(OC(CH3)2), 52.2 (OCH3), 44.3 (2′-C), 39.4 (C(CH3)2), 32.1, 30.3, 24.8, 23.6 (3′-C, 4′-C, 
5′-C, 6′-C), 28.7 (C(CH3)2), 26.0 (OC(CH3)2), 14.6 ppm (7′-C). HPLC-MS: [A, 80% → 
95%]. tR: 4.97 min (98%). MS (ES+, m/z) 358 [M + H]+. Anal. Calcd for C22H31NO3: C 
73.92, H 8.74; found, C 74.11, H, 8.95.
7-(1,1-Dimethylheptyl)-9-(3-hydroxypropoxy)-4,4-dimethyl-4H-chromeno[3,4-
d]isoxazole (44): The title compound was prepared from 42 (50 mg, 0.14 mmol), sodium 
hydride (7 mg, 0.29 mmol), and 3-bromo-1-propanol (99 μL, 0.72 mmol) as described for 
compounds 22–39. Column chromatography on silica gel (hexane/EtOAc, 2:1) afforded 44 
as a yellow oil (13 mg, 22%). 1H NMR (300 MHz, CDCl3) δ: 8.11 (s, 1H, 3-H), 6.69 (d, J = 
1.6 Hz, 1H, 8-H), 6.58 (d, J = 1.6 Hz, 1H, 6-H), 4.15 (t, J = 7.1 Hz, 2H, OCH2CH2CH2OH), 
3.78 (t, J = 4.7 Hz, 2H, OCH2CH2CH2OH), 2.11–2.09 (m, 2H, OCH2CH2CH2OH), 1.65 (s, 
6H, OC(CH3)2), 1.61–1.57 (m 2H, 2′-H), 1.51 (s, 6H, C(CH3)2), 1.23–1.14 (m, 8H, 3′-H, 
4′-H, 5′-H, 6′-H), 0.86–0.80 ppm (m, 3H, 7′-H). 13C NMR (75 MHz, CDCl3) δ: 160.5 (9-
C), 155.7 (9b-C), 154.0 (5a-C), 150.9 (7-C), 143.5 (3-C), 120.6 (9a-C), 108.9 (8-C), 106.3 
(6-C), 105.8 (3a-C), 75.0 (OC(CH3)2), 66.3 (OCH2CH2CH2OH), 62.8 (OCH2CH2CH2OH), 
44.3 (2′-C), 40.1 (OCH2CH2CH2OH), 38.3 (C(CH3)2), 32.7, 31.5, 23.9, 22.6 (3′-C, 4′-C, 
5′-C, 6′-C), 28.3 (C(CH3)2), 27.1 (OC-(CH3)2), 14.7 ppm (7′-C). HPLC-MS: [A, 80% → 
95%]. tR: 2.96 min (95%). MS (ES+, m/z) 402 [M + H]+. Anal. Calcd for C24H35NO4: C 
71.79, H 8.79; found, C 72.06, H, 8.55.
Pharmacological Assays
Radioligand Binding Experiments—Commercial membranes purified from cells 
transfected with human CB1 or CB2 receptors (RBHCB1M400UA and RBXCB2M400UA) 
were supplied by PerkinElmer Life and Analytical Sciences (Boston, MA, USA). The 
protein concentration was 8 μg/well for CB1 and 4 μg/well for the CB2 receptor. The binding 
buffer was 50 mM TrisCl, 5 mM MgCl2, 2.5 mM EDTA, and 0.5 mg/mL BSA (pH 7.4) for 
CB1, and 50 mM TrisCl, 5 mM MgCl2, 2.5 mM EGTA, and 1 mg/mL BSA (pH 7.5) for 
CB2. The radioligand [3H]-CP55940 (PerkinElmer, Boston, MA, USA) was used at a 
concentration of membrane KD × 0.8 nM, and the final incubation volume was 200 μL for 
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CB1 and 600 μL for CB2 receptors. 96-well plates and the tubes necessary for the 
experiment were previously siliconized with Sigmacote (Sigma-Aldrich, Madrid, Spain). 
Membranes were resuspended in the corresponding buffer and were incubated (90 min at 
30 °C) with the radioligand and each compound at a high concentration (40 μM) with the 
purpose of determining the % of radioligand displacement. Only in those cases in which 
radioligand displacement was greater than 70%, a complete competition curve with different 
compound concentrations (10–11–10–4 M) was carried out to obtain the Ki values. 
Nonspecific binding was determined with 10 μM WIN55212-2 (Sigma-Aldrich, Madrid, 
Spain) and total radioligand binding by incubation with the membranes in the absence of any 
compound. Filtration was performed by a Harvester filtermate (PerkinElmer, Boston, MA, 
USA) with Filtermat A GF/C filters pretreated with polyethylenimine 0.05%. After filtering, 
the filter was washed nine times with binding buffer and dried, and a melt-on scintillation 
sheet (MeltilexTM A, PerkinElmer, Boston, MA, USA) was melted onto it. Then, 
radioactivity was quantified by a liquid scintillation counter (Wallac MicroBeta Trilux, 
PerkinElmer, Boston, MA, USA). Competition binding data were analyzed by using 
GraphPad Prism, version 5.02 (GraphPad Software Inc., San Diego, CA, USA), and Ki 
values are expressed as the mean ± SEM of at least three experiments performed in triplicate 
for each point.
cAMP Determination Assays—Determination of cAMP levels in HEK293 cells stably 
expressing the CB2 receptor was performed using the Lance-Ultra cAMP kit (PerkinElmer) 
according to the manufacturer’s instructions. Briefly, HEK293 cells expressing the CB2 
receptor were dispensed in white 384-well microplates at a density of 5.000 cells per well. 
Finally, cells were incubated for 60 min at room temperature with HTRF assay reagents, and 
fluorescence at 665 nm was analyzed on a PHERAstar Flagship microplate reader equipped 
with an HTRF optical module (BMG Labtech). Data analysis was made based on the 
fluorescence ratio emitted by the labeled cAMP probe (665 nm) over the light emitted by the 
europium cryptate-labeled anti-cAMP antibody (620 nm). A standard curve was used to 
calculate cAMP concentration. Forskolin stimulated cAMP levels were normalized to 100%. 
Data was analyzed by using the GraphPad Prism program using nonlinear regression 
analysis. EC50 and Emax values are expressed as the mean ± SEM of at least three 
experiments performed in triplicate.
[35S]-GTPγS Binding Assays
Protocol for CB1 Receptors: Cell Culture—HEK293-CB1R cells were grown to 
confluence under 5% CO2 in Dulbecco’s modified Eagle’s medium (Lonza) containing 10% 
fetal bovine serum (Sigma-Aldrich), 1× penicillin–streptomycin–amphotericin B antibiotics 
(Lonza), and ultraglutamine 2 mM (Lonza). Membrane preparation: cells were washed twice 
with ice-cold phosphate-buffered saline, detached from flasks by incubation with lifting 
buffer (glucose 5.6 mM, KCl 5 mM, HEPES 5 mM, NaCl 137 mM, and EGTA 1 mM, pH 
7.4), and collected by centrifugation (500g). The cells were resuspended in ice-cold lysis 
buffer (MgSO4 0.2 mM, KH2PO4 0.38 mM, Na2HPO4 0.61 mM, pH 7.4) and homogenized 
using a glass-PTFE homogenizer. Crude membranes were isolated by centrifugation for 20 
min at 20,000g. The resulting membrane pellets were resuspended in 50 mM Tris-HCl 
buffer (pH 7.4) and stored at −80 °C in aliquots of 0.8 mg/mL protein determined for Bio-
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Rad DC Protein Assay. All procedures were performed at 4 °C. Agonist-stimulated 
[35S]GTPγS binding: cannabinoid agonist stimulation of [35S]GTPγS binding was 
determined using several concentrations of compounds from 10–4 to 10–11 M and incubated 
with HEK293-CB1R membranes (20 μg/well) for 60 min at 30 °C in assay buffer (100 mM 
NaCl, 50 mM Tris-HCl, 5 mM MgCl2, 1 mM EGTA, 1 mM DTT, 50 μM GDP, 10 mU/mL 
adenosine deaminase, and 1 mg/mL BSA, pH 7.4) containing 0.1 nM [35S]GTPγS 
(PerkinElmer). Nonspecific binding was determined in the presence of 10 μM GTPγS. 96-
Well plates and the tubes necessary for the experiment were previously siliconized with 
Sigmacote (Sigma-Aldrich).
Experiments were terminated by rapid filtration performed by a Harvester filtermate 
(PerkinElmer) with Filtermat A GF/C filters. After filtering, the filter was washed nine times 
with filtration buffer (50 mM Tris-HCl and 1 mg/mL BSA, pH 7.4) and dried, and a melt-on 
scintillation sheet (Meltilex A, PerkinElmer) was melted onto it. Then, radioactivity was 
quantified by a liquid scintillation spectrophotometer (Wallac MicroBeta Trilux, 
PerkinElmer). Data were analyzed by nonlinear regression analysis of sigmoidal dose–
response curves using GraphPad Prism 5.01 (GraphPad, San Diego, CA). EC50 values are 
expressed as the mean ± SEM of at least three experiments performed in triplicate for each 
point.
Protocol for CB2 Receptors—[35S]-GTPγS binding analyses were carried out for 
compounds 34 and 42–44 using CB2R-containing membranes (HTS020M2, Eurofins 
Discovery Services). To this end, membranes (5 μg/well) were permeabilized by the addition 
of saponin (Sigma-Aldrich), then mixed with 0.3 nM [35S]-GTPγS (PerkinElmer) and 10 
μM GDP (Sigma-Aldrich) in 20 mM HEPES (Sigma-Aldrich) buffer containing 100 mM 
NaCl (Merck) and 10 mM MgCl2 (Merck), at pH 7.4. Increasing concentrations of 
compounds 34 and 42–44 (from 10–11 to 10–5 M) were added in a final volume of 100 μL 
and incubated for 30 min at 30 °C. The nonspecific signal was measured with 10 μM 
GTPγS (Sigma-Aldrich). All 96-well plates and the tubes necessary for the experiment were 
previously silanized with Sigmacote (Sigma-Aldrich). The reaction was terminated by rapid 
vacuum filtration with a filter mate Harvester apparatus (PerkinElmer) through Filtermat A 
GF/C filters. The filters were washed nine times with ice-cold filtration buffer (10 mM 
sodium phosphate, pH 7.4), and bound radioactivity was measured with a 1450 LSC & 
Luminescence counter Wallac MicroBeta TriLux (PerkinElmer). [35S]-GTPγS binding data 
were analyzed to determine the EC50 and Emax values by using an iterative curve-fitting 
procedure with GraphPad Prism, version 5.02 (GraphPad Software Inc.). EC50 and Emax 
values are expressed as the mean ± SEM of at least three experiments performed in triplicate 
for each point.
Molecular Modeling
Amino Acid Numbering—The numbering scheme for Class A GPCRs suggested by 
Ballesteros and Weinstein57 was employed here. In this numbering system, the label 0.50 is 
assigned to the most highly conserved Class A residue in each transmembrane helix (TMH). 
This number is preceded by the TMH number and followed in parentheses by the sequence 
number. All other residues in a TMH are numbered relative to this residue.
Morales et al. Page 25













Conformational Analysis of the Compounds—Global minimum energy 
conformations of 5, 7b, 18, and 42 were determined with Spartan’08 (Wave function, Inc., 
Irvine CA) as follows: the structure of each molecule was built from the fragment library 
available in the program. Then, ab initio energy minimizations of each structure at the 
Hartree-Fock 6-31G* level were performed. A conformational search was next implemented 
using Molecular Mechanics (Monte Carlo method) followed by a minimization of the energy 
of each conformer calculated at the Hartree-Fock 6-31G* level. For this search, selected 
bonds were allowed to rotate: C–O bond in the phenolic ring, the first two C–C bonds of the 
dimethylheptyl chain, and the N–C bond in the ethyl substituent of the pyrazole. 
Representative conformers according to their geometry were selected for ab initio energy 
minimization (HF 6-31G*). The global minimum energy conformer of each compound was 
used as input for receptor docking studies.
Electrostatic Potential Map Calculation—The electrostatic potential density surface 
was calculated using Spartan’08 (Wave function, Inc., Irvine CA). The electrostatic potential 
energy was calculated using the Hartree-Fock method at the 6-31G* level of theory and was 
mapped on the 0.002 isodensity surface of each molecule. The surface was color-coded 
according to the potential, with electron rich regions colored red and electron poor regions 
colored blue.
CB1R* and CB2R* Models—The models used for these docking studies were developed 
by P. Reggio and co-workers.46,47 These models are based on the crystal structure of the 
class A GPCR, rhodopsin.58 Complete details on the generation of the activated state models 
were published and properly described by them in the literature.43,46,59,60
Docking Studies—Minimum energy conformers of each ligand were selected for the 
initial docking. Binding site anchoring interactions within the receptor for each ligand were 
based on earlier published docking studies for HU21043 and for AM-841.44,45
Initial steric clashes were removed manually with interactive graphics. The energy of the 
ligand-CBR* TMH bundle complex was minimized using the OPLS2005 force field in 
Macromodel (version 9.1, Schrödinger, LLC, New York, NY). An 8.0-Å extended 
nonbonded cutoff (updated every 10 steps), a 20.0-Å electrostatic cutoff, and a 4.0-Å 
hydrogen bond cutoff were used in each stage of the calculation. All residues except 
D2.50(163), K3.28(192), and D6.58(366) (CB1R model), and D2.50(79), K3.28 (109), and 
D275 (CB2R model), were neutralized during the minimization. C alpha atom restraints (100 
kcal/mol) for all C alpha atoms were applied, and the full bundle was energy minimized 
until an energy gradient of 0.1 kcal/mol was reached. The C alpha atom restraints were then 
reduced in steps to 50 kcal/mol, and 0 kcal/mol (no restraints) until an energy gradient of 0.1 
kcal/mol was achieved at each step. To allow the loops to adjust in their proper environment, 
atoms of the TMH regions were frozen, and the bundle was reminimized in water solvent to 
0.1 kcal/mol gradient with loop residues fully charged.
Energy Expense Assessments for Docked Ligands—To calculate the energy 
difference between the global minimum energy conformer of each compound and its final 
conformation after energy minimization of the ligand–receptor complex, rotatable bonds in 
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the global minimum energy conformation were driven to their corresponding value in the 
final docked conformation, and the single point energy of the resultant structure was 
calculated at the HF 6-31G* level using Jaguar (version 9.1, Schrodinger, LLC, New York, 
NY).
Assessment of Pairwise Interaction Energies—After defining the atoms of each 
ligand as one group (group 1) and the atoms corresponding to a residue that lines the binding 
site in the final ligand-CB R* complex as another group (group 2), Macromodel (version 
9.1, Schrödinger, LLC, New York, NY) was used to output the pairwise interaction energy 
(Coulombic and van der Waals) for a given pair of atoms. The pairs corresponding to group 
1 (ligand) and group 2 (residue of interest) were then summed to yield the interaction energy 
between the ligand and that residue. Total interaction energy for each ligand with the 
cannabinoid receptor was calculated by summing the pairwise interaction energies for all 
residues in the binding site of that ligand and adding to this sum, the conformational energy 
expense for the ligand.
Animals and Theiler’s Virus Infection
All experiments were performed in strict accordance with EU and governmental regulations 
(Decret 53/2013 BOE no. 34 and Comunidad de Madrid: ES 280790000184). The Ethics 
Committee on Animal Experimentation of the Instituto Cajal, CSIC approved all procedures 
described in this study (protocol number: 2013/03 CEEA-IC). Twelve-week-old female 
SJL/J mice (Harlan; Barcelona, Spain) were maintained at Cajal Institute (CSIC; Madrid, 
Spain) in an in-house colony under controlled conditions, on a 12 h light/dark cycle, 
temperature 20 °C (±2 °C) and 40–50% relative humidity, with ad libitum access to food and 
water. Mice were intracerebrally inoculated in the right hemisphere with 2 × 106 plaque 
forming units (pfu) of the Daniel (DA) strain of Theiler’s murine encephalomyelitis virus 
(TMEV), diluted in 30 μL of DMEM supplemented with 10% of fetal calf serum, as 
previously described.61 Sham mice received 30 μL of vehicle. Animals were injected 
intraperitoneally, for 7 consecutive days, with vehicle (10% DMSO in phosphate-buffered 
saline, PBS) or 43 (5 mg/kg).
Immunohistochemistry—Mice were anesthetized by intraperitoneal injection of 
pentobarbital (50 mg/kg body weight) and perfused transcardially with PBS. The brain of 
each animal was fixed in 4% paraformaldehyde (PFA) diluted in 0.1 M phosphate buffer 
(PB), cryoprotected in a 30% solution of sucrose in 0.1 M PB, and frozen at −80 °C until 
used. For immunofluorescence studies, the sections were rinsed three times for 10 min with 
0.1 M PB, blocked as above, and then incubated overnight with the primary antibody against 
Iba1 (ionized calcium binding adaptor molecule 1, 1:1,000; Wako Chemical Pure Industry, 
Osaka, Japan). After washing three times for 10 min with 0.1 M PB, the sections were 
incubated for 1 h with an Alexa Fluor-conjugated secondary antibody (1:1,000; Molecular 
Probes Inc., Eugene, OR, USA). The sections were mounted with mowiol. Six brain sections 
per animal from at least 5 animals per group were analyzed. Quantification of staining was 
performed using the ImageJ software (NIH; Bethesda, MD, USA).
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Statistical Analysis—The SPSS 22 software (IBM Corporation; USA) was used for the 
statistical analysis, applying the nonparametric Kruskal–Wallis test. All of the data are 
presented as the mean ± standard error of mean (SEM). A value of p < 0.05 was considered 
statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Structures of Δ9-tetrahydrocannabinoid (Δ9-THC) and the previously identified CB1 fully 
selective chromenopyrazoles.34
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cAMP screening in HEK293-CB2R cells. Results are expressed as percent of forskolin (Fk)-
stimulated cAMP accumulation at a concentration of 200 nM and 1 μM of 16–18, 22, 28, 31, 
34, 35, 37, 39, or 41–44. All data result from at least three independent experiments, 
performed in triplicate.
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Effect of compounds 16, 31, and 35 on CP55,940-induced inhibition of cAMP accumulation 
in HEK293-CB2R cells. (A) 16 at 200 nM; (B) 34 at 200 nM; (C) 31 at 200 nM; (D) 31 at 1 
μM. All data result from at least three independent experiments, performed in triplicate. Data 
were assessed by one-way analysis of variance (F(5,43) = 20.57, p < 0.0001 for 16; F(5,42) 
= 17.92, p < 0.0001 for 35; F(5,33) = 27.16, p < 0.0001 for 31 (C); F(5,33) = 22.03, p < 
0.0001 for 31 (D); *p < 0.05, **p < 0.01, ***p < 0.005 compounds alone versus control (Fk 
cAMP accumulation); and p < 0.05, p < 0.01, and p < 0.005 CB2 agonist versus CB2 agonist 
+ 16, 31, or 35.
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Molecular electrostatic potential maps of the minimum energy conformations of 5, 7b, 18, 
and 42 are illustrated here. The electrostatic potential scale (in kJ/mol) is provided as a color 
scale. This scale is from blue (most electropositive) to red (most electronegative).
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Binding site of 5 (panel A) and 42 (panel B) in the CB1R* model. Side view of ligand/
receptor complexes as if looking through TMH1 (not displayed). Hydrophilic interacting 
residues are represented with yellow carbons. Hydrogen bonds are shown with yellow 
dashed lines. Select hydrophobic interacting residues, F2.57 and L7.43, are displayed with 
green carbons.
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Binding site of 42 (panel B, in purple) in the CB2R* model. Side view of the ligand/receptor 
complex as if looking through TMH1 (not displayed). Hydrophilic interacting residues are 
represented with yellow carbons. Hydrogen bonds are shown with yellow dash lines. A 
selected hydrophobic interacting residue, V3.32, is displayed with green carbons. Structure 
of 5 (panel A, in cyan) was superimposed on the 42-CB2R* complex. The magenta circle 
indicates van der Waals steric overlap of 5 with K3.28, which forms a salt bridge with 
D(275) in the CB2R* binding site.
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Binding site of 18 (panel B, in orange) in the CB2R* model. Side view of the ligand/receptor 
complex as if looking through TMH1 (not displayed). Hydrophilic interacting residues are 
represented with yellow carbons. Hydrogen bonds are shown with yellow dash lines. A 
selected hydrophobic interacting residue, V3.32, is displayed with green carbons. Structure 
of 7b (panel A, in pink) was superimposed on the 42-CB2R* complex. The magenta circle 
indicates van der Waals steric overlap with K3.28, D(275), and F7.35. The residues K3.28 
and D(275) form a salt bridge within the CB2R* binding site.
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Compound 43 significantly reduces microglial activation on TMEV-infected mice. (A) Brain 
sections were stained with an anti-Iba1 Ab for microglia labeling and analyzed by confocal 
microscopy. Representative images are shown. Fluorescence intensity was measured with 
ImageJ software and plotted to show quantification of the analyzed images (B), mean ± 
SEM *p < 0.05 vs Sham, #p < 0.05 vs TMEV+veh, in a nonparametric Kruskal–Wallis test. 
Scale bar: 50 μm.
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Synthesis of Chromenopyrazoles 5–39a
aReagents and conditions: (i) BBr3, CH2Cl2, overnight, from 0 °C to rt, 92%; (ii) 3,3-
dimethylacrylic acid, methanesulfonic acid, P2O5, 8 h, 70 °C, 81%; (iii) (a) NaH, THF, MW, 
25 min, 45 °C; (b) ethyl formate, MW, 25 min, 45 °C, 76%; (iv) corresponding hydrazine, 
EtOH, 1–4 h, 40 °C, 36–50%; (v) (a) NaH, THF, 10 min, (b) 1-bromo or iodoalkane, 8–72 h, 
reflux, 36–50%.
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Synthesis of Pyrano-chromenopyrazoles 40 and 41a
aReagents and conditions: (i) P2O5, toluene, 3 h, reflux, 36–66%.
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Synthesis of Chromenoisoxazoles 42–44a
aReaction conditions: (i) hydroxylamine hydrochloride, acetic acid, 15 min, reflux, 91%; (ii) 
(a) NaH, THF, 10 min, 0 °C; (b) 1-bromo or iodoalkane, 8–72 h, reflux, 36–50%.
Morales et al. Page 42

























Morales et al. Page 43
Table 1
Binding Affinity of Chromenopyrazoles 5–14 and Reference Cannabinoids for hCB1 and hCB2 Cannabinoid 
Receptors
CB1 CB2 CB1 CB2








5 34 H 28.5 ± 23.7 >40000 >1400
6b 34 N2-Me 14.2 ± 2.9 >40000 >2500
7a 34 N1-Et 4.5 ± 0.6 >40000 >8000
7b 34 N2-Et 18.6 ± 2.9 >40000 >2000
8 34 N1-3,4-diClPh 514 ± 205 270 1.9
9 34 N1-2,4-diClPh 5.2 ± 4.3 >40000 >7500
10a N1-(CH2)2OH 19.1 ± 8.9 366 ± 169 19.1
10b N2-(CH2)2OH 54.4 ± 8.1 39.6 ± 7.1 1.4
11 N2-CH2OH 218.1 ± 40.5 59.4 ± 31.2 3.7
12 N1-3,5-diFPh >40000 >40000
13 N1-3-OMePh 6440 ± 655 562.0 ± 13.2 11.5
14 N1-Cy 1140 ± 190 53.7 ± 11.8 - 21.5
SR141716 7.3 ± 0.9 >40000 >5400
WIN55,212-2 45.6 ± 8.6 3.7 ± 0.2 12.3
a
Ki: affinity constants. Values were obtained from competition curves using [3H]CP55940 as radioligand for hCB1 and hCB2 cannabinoid 
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Table 2
Binding Affinity of Chromenopyrazoles 15–41 for hCB1 and hCB2 Cannabinoid Receptors
CB1 CB2 CB1 CB2








15 H Me 272 ± 75 87.1 ± 10.6 3.1
16 N2-Me Me 4159 ± 542 66.4 ± 13.29 62.6
17 N1-Et Me 5040 ± 670 159.5 ± 31.2 31.6
18 N2-Et Me 2930 ± 470 92.6 ± 17.1 31.8
19 N1-3,4-diClPh Me 2324 ± 327 2256 ± 499
20 N1-2,4-diClPh Me 1693 ± 239 1493 ± 272
21 N1-3,4-diClPh Et >40000 3545 ± 89 >11.3
22 H Bn 22.4 ± 4.1 93.3 ± 29.5 4.2
23 N2-Me Bn 702.4 ± 98.6 208.8 ± 39.5 3.3
24 N1-Et Bn 613.7 ± 206.9 295.9 ± 53.6 2.0
25 N2-Et Bn 671.3 ± 166.1 212.2 ± 49.4 3.1
26 N1-3,4-diClPh Bn >40000 3740 ± 297 >10.7
27 N1-2,4-diClPh Bn >40000 >40000
28 H (CH2)3OH 450.4 ± 9.9 26.0 ± 7.1 17.3
29 N2-Me (CH2)3OH >40000 364.0 ± 68.9 >109.9
30 N1-Et (CH2)3OH 1613 ± 284 440 ± 145 3.6
31 N2-Et (CH2)3OH >40000 97.4 ± 9.9 >410.7
32 N1-2,4-diClPh (CH2)3OH >40000 >40000
33 N1-3,4-diClPh (CH2)3OH >40000 >40000
34 H (CH2)2OH 64.8 ± 18.0 3.6 ± 0.7 18
35 N2-Me (CH2)2OH 1086 ± 198 39.8 ± 24.9 27.2
36 N2-Et (CH2)2OH 6512 ± 714 210.6 ± 93.2 31.0
37 N2-Me (CH2)3Br 1482 ± 221 77.3 ± 0.87 19.1
38 N2-Et (CH2)3Br 657 ± 159 87.1 ± 14.2 7.5
39 N1-Et (CH2)2Br 1331 ± 320 78.7 ± 11.3 16.9
40 N1-Et >10000 563.8 ± 13.1 >17.7
41 N2-Et >40000 121.6 ± 43.5 >330.5
a
Ki: affinity constants. Values were determined from competition curves using [3H]CP55940 as radioligand for hCB1 and hCB2 cannabinoid 
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Table 3
Binding Affinity of Chromenoisoxazoles 42-44 for hCB1 and hCB2 Cannabinoid Receptors
CB1 CB2 CB1 CB2








42 H 15.4 ± 12.2 5.3 ± 0.8 2.9
43 Me >40000 12.8 ± 2.4 >3100
44 (CH2)3OH 332.6 ± 143.9 65.5 ± 21.8 5.1
a
Ki: affinity constants. Values were obtained from competition curves using [3H]CP55940 as radioligand for hCB1 and hCB2 cannabinoid 
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Table 4
Functional Potencies of 34 and 41–44 and Reference Cannabinoids at the CB2 Receptor Determined by 
Measuring the Decrease in Forskolin-Stimulated cAMP Levels in HEK293-CB2R Cells or by [35S]-GTPγS 
Binding to the hCB2 Receptor










34 21.6 ± 1.5 95 ± 6 95.1 ± 7.2 110 ± 17
41 25.5 ± 2.0 98 ± 11 n.d. n.d.
42 134.0 ± 2.3 98 ± 9 50.2 ± 24.9 114 ± 37
43 4.2 ± 1.5 101 ± 10 38.6 ± 6.7 98 ± 8
44 14.0 ± 1.9 91 ± 10 539.6 ± 208.1 96 ± 15
CP55,940 8.3 ± 1.5 100 ± 9 n.d. n.d.
JWH133 81.8 ± 1.7 98 ± 11 n.d. n.d.
HU308 n.d. n.d. 64.5 ± 1.6 91 ± 7
a
IC50 values were calculated using nonlinear regression analysis. Data are expressed as the mean ± SEM of at least three independent experiments, 
each one run in triplicate.
b
Forskolin stimulated cAMP levels were normalized to 100%. Emax is the maximum inhibition of forskolin stimulated cAMP levels.
c
EC50 values were calculated using nonlinear regression analysis. Data are expressed as the mean ± SEM of at least three independent 
experiments, each one run in triplicate.
d
Emax: maximal agonist effect, determined using nonlinear regression analysis.
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Table 5








10b 298.8 ± 54.2 97 ± 52
22 191.0 ± 90.8 234 ± 79
42 15.8 ± 8.6 196 ± 111
WIN55,212 44 ± 30 153 ± 70
a
EC50 values were calculated using nonlinear regression analysis. Data are expressed as the mean ± SEM of at least three independent 
experiments, each one run in triplicate.
b
Emax: maximal agonist effect, determined using nonlinear regression analysis.
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